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Abstract 
Treatment outcomes and prognostic accuracy for oral tongue cancer has had little 
substantial improvement in the last 20 years. Adjuvant therapy toxicity is high, and 
there are no clinical tests that accurately stratify which high-risk cancers are likely to 
benefit, and which will recur despite treatment. Genomic instability is an inherent 
force in all cancer, however there are substantial differences in which defective 
repair pathways cause malignancy and contribute to invasion and metastasis. 
Tongue cancer is relatively aetiologically homogenous, as it is associated mostly 
with tobacco exposure, exhibits early lymphatic invasion, and is sensitive to 
particular DNA-damaging agents, making it an attractive disease target for 
investigating the prognostic potential of genomic stability markers. The aim of this 
study is to evaluate the prognostic and predictive implications of genomic instability 
in primary oral tongue cancer. 
  
Molecular tumour diagnostics is a burgeoning field, complicated by a paucity of well-
powered trials demonstrating clinical outcomes. DNA repair proteins as biomarkers 
have been mostly studied in genetic assays, from severe repair syndrome 
phenotypes to BRCA gene inactivation in breast and ovarian cancer. De-novo 
mutations in repair genes have been less frequently characterized across sporadic 
or exposure-related cancers. Almost all cancers exhibit mutation of nuclear DNA 
resulting in deregulation of the cell cycle and repair process. The most deleterious 
lesion is the double-strand break (DSB), and defects in this repair pathway cause 
both increased aggressive features (heterogeneity, invasion and metastasis) and 
sensitivity to chemoradiotherapy.  
This study will examine eight markers of genomic stability across three principal 
domains;  
 
1. Markers of repair of specific lesions induced by standard chemotherapy for 
oral tongue cancer (treatment prediction) 
2. Markers implicated in genetic susceptibility studies in oral squamous cell 
cancer (phenotype stratification) 
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3. Markers of the DNA damage response and DSB repair (genomic stability) 
 
A key study strategy is the creation and utilisation of a tissue microarray resource to 
economically assess the relatively large number of markers in the context of limited 
source tissue. A microarray of fifty-five (55) included patients was constructed from 
stored surgical specimen blocks. Immunohistochemical stains were performed, and 
grading scales constructed under the guidance of a clinical pathologist (Dr Duncan 
Lambie). 
The hypothesis of this study is that genomic instability of primary tumours is a 
characteristic that is important for both prognosis and treatment prediction, and that 
this can be quantified using immunohistochemical methods. We have identified two 
important patient subgroups that show significant prognostic differentiation in our 
markers and discuss the implications for clinical management.
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Chapter 1. Introduction 
Oral tongue cancer survival has shown only modest improvement in the last twenty 
years, despite steady improvement in adjuvant and targeted therapy in other cancer 
types, and is behaviourally distinct from the prognostically-favourable HPV-16 
related oropharyngeal  cancer.   
The genetic basis for cancer is genomic instability, and defects in the mechanisms 
underlying repair of DNA lesions are implicated in both carcinogenesis and 
development of migratory and evasive features in the cancer genome. Adjuvant 
therapy conventionally exploits these defects to selectively damage malignant cells, 
however the same mutagenic potential can accelerate development of drug or 
radiation resistance mechanisms. This multifactorial aspect of the DNA damage 
response makes single-marker studies difficult to interpret, and offers an opportunity 
to characterise tumour phenotype by the pattern of expression of DNA repair 
proteins. This has promise for prognostic decision making, treatment prediction and 
for identification of future drug targets to potentiate lethality. 
This study will assess the expression of the DNA damage response (DDR) in a 
retrospective cohort of oral tongue squamous cell carcinoma, using 
immunohistochemical (IHC) analysis of a panel of twelve (12) important repair 
proteins via a tissue microarray (TMA). Correlation of DDR proteins with database 
and manual chart review data will be analysed to generate survival graphs for each 
DDR phenotype. Two important subpopulations are identified that exhibit significant 
survival differences on a biomarker panel; these are differentiated on radiotherapy 
treatment, and surgical margin clearance. 
Cancer subtypes expressing homologous recombination (HR) defects will be 
assessed on outcome, and particularly for potential synthetic lethality with poly 
(ADP-ribose) polymerase (PARP)-inhibiting agents (discussed further on page 22). 
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Chapter 2. Literature review 
Section 2.01 Tongue and oral squamous cell carcinoma; epidemiology 
and current treatment 
Cancer is the leading cause of mortality in the developed world, and an increasing 
disease burden in the developing world [3]. Our understanding of the genetic basis 
for the pathogenesis of malignancy is improving substantially, and targeted therapies 
to selectively exploit properties of cancerous cells have significantly improved 
survival in some of the most common cancer subtypes [4, 5]. In contrast, there have 
been only modest improvements in overall and disease-specific survival for oral-
cavity squamous cell carcinoma in the last 30 years [6, 7] and no significant 
improvement in early diagnosis [8, 9] 
Incidence in the Australian population is low relative to the international average, at 
2.1% of the cancer burden and 0.8% lifetime risk  (compared with the European 
average of 2.6% and 1.3% respectively) [3, 9]. However, incident migrant 
populations from South-East Asia are at much greater risk [10, 11]. Incidence is 
much higher in Asia; in India it is among the top three causes of cancer death, in 
some regions accounting for up to 40% of all cancer deaths, and is continuing to 
climb [12, 13]. 
(a) Risk factors 
Established risk factors in carcinogenesis of the tongue and oral cavity include 
smoking, alcohol consumption, smokeless tobacco, betel quid consumption with 
slaked lime and other culturally-specific alkaloid stimulants [11, 14-16]. While no 
threshold quantification studies have been done in oral cavity cancer, in a larger 
series of oropharyngeal carcinoma 10 pack-years of exposure was found to be a 
significant risk threshold (HR2.10)[17]. Exposure to these chemical carcinogens is 
associated with the development of premalignant lesions called leukoplakia and 
erythroplakia, collectively termed oral potentially malignant disorders (OPMD) [8, 18]. 
Approximately 25% to 32% of mobile tongue leukoplakia and up to 65% of 
erythroplakia lesions demonstrate moderate to severe dysplasia or carcinoma on 
histology, genomic instability and early loss of tumour-suppressor genes [19]. 
Malignant transformation rates have been inconsistently reported from 0.13 to 17.5% 
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per year [8, 20-23], owing to population differences and difficulty with interobserver 
variability.  
High-risk human papillomavirus (HPV16 and HPV18 specifically) has been shown to 
be responsible for the increasing incidence of HNSCC generally [24]. HPV-
associated SCC is associated with a viral E6 and E7 oncoprotein-driven cell-cycle 
deregulation [25-27], typically affects younger patients and has an improved 
prognosis [28, 29]. While high-risk HPV co-infection is present in up to 30% of oral 
cavity SCC [30], a direct pathogenesis link is much less clear than other head and 
neck subsites [31]. Indeed, tumour suppressor protein p16, which is 
pathognomonically elevated in HPV-associated SCC, is down-regulated in 56-63% 
of oral SCC [32-34], while p16 elevation is far less frequent in HPV-associated oral 
cavity SCC [35].  More recently found in younger HPV16-negative patients is an 
increasing subset of aggressive oral tongue SCC with a weaker association with 
smoking, which may have a genetic basis [15, 36-40]. Together with the high 
prevalence of occult HPV infection, these data suggest no clear aetiological link with 
oral cavity cancer. 
(a) Occult metastasis and surgical management 
Squamous cell carcinoma of the tongue has a high rate of metastasis at diagnosis, 
with 44% of patients presenting in the United States found to have regional 
metastasis and 14% distant [6].  Clinical examination for regional metastasis is 
unreliable with a sensitivity of 69% [41] and microscopic metastasis is frequently 
present below the imaging threshold of MRI or CT [42]. The dense lymphatic 
drainage of the tongue to the cervical lymph nodes contributes to a high occult 
metastatic rate for small primary tumours, with 32- 42% of clinically and radiologically 
node-negative T1 & T2 tumours demonstrating lymphatic metastasis on neck 
dissection in a number of well-powered trials [41-45]. Due to this rich lymphatic 
drainage, tumour invasion depth and type is a more sensitive indicator for occult 
metastasis and prognosis in early tongue cancer than T-stage [46-49].  Lymphatic 
drainage is typically dictated by anatomical site, with anterior tongue drained 
bilaterally to level I and II, lateral tongue ipsilaterally to levels I - III, and central 
tongue bilaterally via a sublingual node to levels I - III [50]. Submental, low jugular 
and posterior cervical nodes are rarely involved [51]. While usually following a linear 
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progression, occult skip metastases have been found in 8-10% of clinically-negative 
neck dissections [42]. The finding of occult metastatic disease on histology 
independently confers a significantly worse prognosis, lowering 5-year survival from 
65 - 78% to 20 - 22% in T1-T2 disease [43, 45, 52]. 
Surgical management of OSCC has become increasingly aggressive due to the high 
rate of occult disease, and the benefit of elective neck dissection in the clinically 
node-negative neck has been validated retrospectively in Australian populations, for 
thick (>4mm) T1-T2 disease [53], and in larger meta-analyses [54, 55]. Recurrent 
OSCC is associated with significantly higher morbidity and lower survival, and 
salvage surgery is complicated by more aggressive local invasion, post-surgical and 
adjuvant scarring and wound-healing changes, and the presence of co-morbidities 
[56]. Suitability of patients for salvage surgery is low, with rates of 33% reported, and 
a subsequent overall 5-year survival of 24% [57], highlighting the importance of 
primary curative success rates and local control.  
(b) Radiation therapy 
Post-operative or adjuvant external-beam radiotherapy is the standard of care for 
most locally or regionally advanced oral cavity cancers [58], however is associated 
with significant dose-dependent toxicity, particularly mucositis, xerostomia, trismus, 
and osteoradionecrosis [59]. Recurrent or second primary cancers in irradiated 
regions are more difficult to surgically resect, and subsequent radiation doses are 
significantly limited. Altered fractionation, dose and modulation regimens have 
shown mixed benefit in HNSCC [59-63].  
(c) Chemotherapy 
Chemotherapy is usually indicated in addition to radiotherapy in unresectable 
disease or locally-advanced disease with high risk of metastasis (features including 
extracapsular spread (ECS) and positive or close margins)[64, 65]. Appropriate 
patient selection for systemic therapy depends on accurate pathological staging. 
Chemotherapy regimens are based on platin compounds, prototypically cisplatin, 
with or without 5-fluorouracil ('PF' regimen) [66], with greatest effect when given 
concurrently with radiotherapy [67, 68]. The absolute 5-year survival benefit 
conferred by concurrent PF chemotherapy is a modest 4.5% (Refer Figure 2.01-1) 
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[67, 69], and is associated with significantly increased treatment morbidity and 
mortality [70]. 
 
Figure 2.01-1 -  Survival in trials comparing locoregional treatment plus chemotherapy with locoregional 
treatment alone [67]. 
Newer chemotherapeutic agents in OSCC include taxols and epidermal growth 
factor receptor (EGFR)-inhibitors, which belongs to the same receptor family as 
HER2 and have downstream effects on DNA repair. Addition of docetaxel, a mitotic 
spindle stabilizer, to PF induction chemotherapy has been shown to confer an 
additional survival benefit [71], although heterogeneity between trial treatment arms 
and high loss-to-followup make absolute benefit difficult to interpret.   
Cetuximab, an IgG1 monoclonal antibody against the EGFR receptor domain, has 
been shown to add an 8% absolute 2-year survival advantage as a monotherapy 
adjunct to radiotherapy  in locally advanced HNSCC, which has subsequently been 
validated to 5 years [72, 73] and become incorporated into standard management of 
late-stage disease [65]. EGFR has been shown to be highly expressed in 23 to 
59.5% of OSCC [74, 75], and there is some evidence these tumours benefit from 
altered radiotherapy fractionation [76].  
Section 2.02 Prognostic modelling 
Prognosis in oral squamous cell carcinoma is multifactorial. Twenty-one percent of 
patients with HNSCC have moderate to severe medical co-morbidities [77], as a 
result of the older median age of onset, and associated tobacco and alcohol use. 
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Overall survival (OS) and disease-specific survival (DSS) are generally used as 
endpoints, with OS having greater clinical significance, and DSS allowing more 
accurate trial comparisons. Event-free survival (EFS), a composite surrogate 
endpoint including death, local or distant recurrence, has also been validated in 
HNSCC [78]. 
Clinical risk factors in oral cavity cancer are sex, smoking, tumour TNM stage and 
co-morbidities. Never-smokers and women typically have more aggressive disease 
and poorer survival. Histopathological markers of risk are involved margins, 'close' 
margins, lymphovascular invasion, lymphocytic infiltrate, tumour depth, nodal yield, 
extracapsular spread and histological grade (Refer Appendix A). Perineural invasion 
is a controversial prognostic indicator for recurrence in the absence of regional 
perineural spread [48, 79].  
Co-morbidity is a well-recognised semi-dependent prognostic factor [77, 80]. The 
Adult Comorbidity Evaluation-27 (ACE-27) (See Appendix B) is a 27-question 
checklist developed as a generalised comorbidity stratification tool for cancer [81], 
subsequently validated in HNSCC [77, 82]. 
An important factor in prognostic modelling is lapsed time since treatment, as 80% of 
recurrences occur  within two years at a median of six months [83]. Methods to 
dynamically calculate prognosis have been developed, but are hampered by the 
need for an unrealistically large data set [84, 85].  
(a) Biomarkers in prognosis and prediction 
A biological marker ('biomarker') is a generic term for a characteristic that is 
objectively measured and evaluated as an indicator of either i) normal biological 
processes, ii) pathogenic processes, or iii) pharmacologic responses to a therapeutic 
intervention [86]. Treatment prediction and prognosis are distinct outcomes with 
biomarker studies. Molecular tumour diagnostics is a burgeoning market, expanding 
from $3 billion USD to $6.2 billion USD between 2005 and 2010 [87]. While there 
has been significant progress in biomarker-driven personalised therapy in solid 
tumours such as lung and breast cancer, there has been relatively less work on 
epithelial cancers [88]. 
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Prognostic and predictive tumour biomarkers have been previously investigated via 
immunohistochemical (IHC) methods, mRNA expression assays, direct DNA stability 
methods (CNR/MSI) and non-tumour cell background susceptibility (primarily 
peripheral blood leukocytes) using SNP panels. Targeted biomarker studies in 
HNSCC have been conducted against markers of apoptosis & proliferation [89-91], 
growth factor receptors [92-94], cell cycle regulators [95, 96], neoangiogenesis 
promoters (such as Vascular Endothelial Growth Factor, VGEF) [94, 97], drug 
resistance [98], hypoxia [99-101], and proteins involved in DNA repair [102-111].  
Cancer biomarker tests range in complexity [112], and increased complexity and 
personalisation makes generalised application of diagnostic tests and clinical 
validation difficult. A recent CDC working group on genomic testing established three 
principal domains of validity in genomic biomarker diagnostics [113], specified for 
this project; 
1. Analytic validity: The test accuracy for the true level of the protein in question. 
This includes IHC specificity and sensitivity to qualitatively 'low', 'medium', or 
'high' true protein concentrations. This is affected by antibody binding 
specificity, functional point mutations that retain antibody binding specificity, 
and tumour heterogeneity.  
2. Clinical validity: The degree to which the altered protein level corresponds to 
the phenotype of "treatment-resistant tongue cancer". This is affected by 
many factors including post-translational modifications (including 
phosphorylation, acetylation, etc.), non-tested functional cofactor depletion, 
functional redundancy or compensation from other systems. 
3. Clinical utility: The degree to which the test can minimise unnecessary 
comorbidity by stratifying and improving selection of patients for aggressive 
adjuvant therapy, predicting therapeutic response to specific adjuvant 
treatments and improving prognostic accuracy. This is affected by both 
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previous domains of validity in addition to issues surrounding the practical 
delivery of the test in the clinical setting. 
Section 2.03 Genomic Stability and Cancer 
(a) DNA repair and the DNA damage response (DDR) 
Highly conserved across all domains of life is a robust DNA damage recognition and 
repair system. Genomic material, both DNA and RNA, is under constant degradation 
from intrinsic and extrinsic factors. These include oxidative stress, ultraviolet 
radiation, ionising radiation, and other chemical alterations such as alkylation [114, 
115]. Cells are particularly sensitive to DNA damage when they are undergoing 
active replication, a fact exploited by chemotherapy and external-beam radiation. 
There are many different types of DNA lesions, which are broadly dealt with via 6 
main interacting pathways; 
1) Direct reversal 
2) Mismatch Repair (MMR) 
3) Nucleotide Excision Repair (NER) 
4) Base Excision Repair (BER) 
5) Single-strand break repair (SSB-R) 
6) Double-strand break repair (DSB-R) 
The most severe form of DNA damage is the double-strand break [116]. BER and 
NER pathways involve SSB DNA intermediates, which unrepaired become DSBs 
when encountered by a replication fork [116, 117]. DSB-R occurs via two pathways, 
non-homologous end-joining (NHEJ) and homologous recombination (HR). The 
primary pathway in non-replicating mammalian cells is NHEJ [117]. 
Hyperplastic, dysplastic and malignant lesions experience replication stress, which 
describes the disorganised replication of genomic DNA as a result of cell-cycle 
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deregulation. The DNA damage response (DDR) is a highly conserved pathway that 
is activated on the basis of a 'threshold' of DNA damage events to inhibit cell cycle 
progression via checkpoint signalling for either repair or apoptosis, and is 
constitutively active in dysplastic lesions [117-119]. This provides an environment of 
constant mutagenic stress with selective pressure for inactivation of growth 
restricting/apoptotic processes [118, 120]. 
(b) The DNA Damage Response 
The DDR is principally mediated by two phosphatidylinositol 3-kinase-related kinases 
(PIKKs), ataxia-telangectasia mutated (ATM) and ataxia- and Rad3-related (ATR). 
ATM preferentially binds to dsDNA free ends (at DSB sites) and in response to IR, 
while ATR preferentially detects base lesions and UVR photoproducts, and is 
activated under conditions of replication stress [121]. These enzymes then 
phosphorylate a large number of downstream mediators that recruit other DDR 
proteins and induce the G2/M, intra-S or G1-S damage checkpoint. The principal 
immediate mediators in these pathways are “mediator of DNA damage checkpoint 1” 
(MDC1), γH2AX, 53BP1, RING-finger protein 8 (RNF8) and BRCA1. Limited studies 
in ATM have shown a strong increased cancer risk with a specific SNP in an East 
Asian population [122]. Promoter hypermethylation of ATM has been linked with 
early age of onset and poor prognosis in one mixed subsite study [123], however this 
has not been reproduced in a large oral cavity cancer series [124].  
(i) γH2AX 
Histones are large structural proteins responsible for efficient packing of DNA into 
compartmental nucleosomes, and have many roles in chromatin remodelling, 
replication, transcription and DNA damage recognition. On exposure to a DSB, large 
areas of adjacent H2A-variant H2AX are rapidly phosphorylated by MDC1 at serine 
139 to become γH2AX. The rapidity and extent of this reaction (up to 2Mb of 
adjacent DNA) has made IHC detection of γH2AX a sensitive surrogate test for 
detection of DSBs [125, 126]. γH2AX is also required for retention of 53BP1 and 
amplification of DDR mediators, particularly under conditions of low-level DNA 
damage [127].  
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(ii) p53 binding protein 1 (53BP1), MDC1 and RNF8 
53BP1 co-localises early and independently of ATM to DSB sites [128] in both a 
direct and MDC1-dependent manner [129-133], where it is hyperphosphorylated 
[134]. It acts as a transcriptional coactivator of tumour suppressor p53 [135], as a 
cofactor for phosphorylation of targets of ATM (such as SMC1), protection of 
exposed DNA ends, and efficient activation of the G2/M damage checkpoint [119].  
E3 ubiquitin-protein ligase RNF8 and RNF168 (RNF8), and ubiquitin-conjugating 
enzyme UBC13 (UBC13) also colocalise early in an MDC1-dependent manner, and 
synthesise a Lys 63-linked ubiquitin chain on H2A and H2AX in an MDC1-dependent 
manner, which enhances recruitment and retention of 53BP1 and BRCA1 [136]. 
UBC13 is preferentially activated in UV-induced damage and RNF8 in IR-induced 
damage [137]. A more recently discovered paralogous E3 ubiquitin ligase RNF169 
has been found to competitively bind to RNF8/RNF168 ubiquitinated H2A/H2AX to 
negatively regulate binding of ubiquitin-dependent DSBR factors such as 53BP1 and 
BRCA1-RAP80 [138]. Discussed further below, blockade of BRCA1-RAP80 
upregulates HR at the expense of genomic stability [139]. BRCA1 and 53BP1 are 
competitive antagonists, with G1 predominantly 53BP1-RIF1 (NHEJ) and G2/S 
phase supporting BRCA1 (HR) foci [140]. 
In BRCA1-deficient tumours, 53BP1 potentiates the DDR and cell-cycle arrest by 
blocking HR repair proteins from docking to the site via recruitment of RIF1 [140, 
141]. Accordingly, subsequent mutations causing downregulation of 53BP1 rescues 
BRCA1-induced growth defects and reduces chemosensitivity [142] and synthetic 
lethality from PARP inhibition. RNF8 may directly load the Rad51 complex in the 
absence of BRCA1 and 53BP1 in one possible alternative HR pathway [143]. 
(iii) Significance 
 ATM is a central upstream regulator of the DSB arm of the DNA damage 
response. 
 γH2AX is a sensitive marker for DSB lesions and the initiation of the DDR. 
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 53BP1 is a proximal marker and effector of efficient DDR activation, limits an 
aggressive phenotype in BRCA1 -/- breast cancer, and paradoxically has a 
small treatment benefit by indirect proteasome inhibition in mantle cell 
lymphoma. 
 RNF8 is a proximal marker and effector of efficient DDR activation, is a 
backup HR initiator in the absence of BRCA1 and 53BP1, and is preferentially 
induced by IR (c.f. UBC13). It has an important role in PARP inhibitor 
resistance. 
(c) Double-stranded DNA break repair (DSB-R) 
Unrepaired SSB lesions will progress to a DSB when encountered by a replication 
fork, while  other lesions such as ICL's will include a DSB as an intermediate step.  
The repair of DSB lesions is via one of three principal pathways, non-homologous 
end joining (D-NHEJ), alternative NHEJ (B-NHEJ) and homologous recombination 
(HR). The pathway used is dependent on cell cycle phase [144] and nature of the 
DSB [145]. 
(i) Non-homologous end joining 
The dominant DSB repair mechanism in somatic cells is NHEJ, which is error-prone, 
operates in all stages of the cell cycle [146], and is essential in normal B-cell V(D)J 
recombination [117]. Eight principal proteins are involved in this pathway; the DNA-
dependent protein kinase (DNA-PK) complex (comprised of Ku70, Ku80 and DNA-
PKcs), XRCC4-DNA Ligase IV (Lig4) complex, Artemis and Cernunnos-XLF.  
In the classical model (D-NHEJ), Ku70 and Ku80 (Ku) bind free dsDNA ends, then 
recruit DNA-PKcs to form the DNA-PK heteromer, with end-processing via DNA-PK -
activated endonuclease Artemis and polynucleotide kinase (PNK) [147]. The ligase 
complex XRCC4-Lig4 then binds and directly re-joins the processed ends in a DNA-
PK -dependent manner [146]. Topoisomerase inhibitors create a complex that 
requires preprocessing by the HR-related end-processing C-terminal binding protein-
interacting protein (CtIP) and MRN complex [148].   
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An alternative pathway (B-NHEJ) is also present in eukaryotic cells [149]. This 
pathway is DNA PK-independent, is downregulated under physiological conditions in 
the presence of Ku70/Ku80 [150], and is more likely to generate chromosomal 
aberrations [149]. Poly(ADP-ribose) polymerase 1 (PARP-1) binds the processed 
ssDNA ends, and builds a ADP-ribose polymer 'flag' to enhance recruitment of 
XRCC1/DNA Ligase III (Lig3) in a manner similar to the typical repair of SSB and 
BER [151], which directly ligates the free ends [152]. Lig3 may also repair DSBs in a 
very inefficient manner in the absence of PARP-1 [152]. This pathway has also been 
termed microhomology-mediated end joining (MMEJ) as it is promoted by the 
presence of short repetitive base sequences (microhomologies) at the break site 
[153, 154].  
(ii) Ku70 and Ku80 
The Ku heterodimer comprised of Ku70 and Ku80 functions as a sensor, binding to 
free dsDNA ends, an end-processing 5'-dRP/AP lyase, and a recruitor of DNA-PKcs 
[155], and telomere protection [156].  
Ku80 overexpression has been linked to poor prognosis, local failure and recurrence 
following radiation [103]. While this study did not include tongue cancer specimens, 
the predictive value was greatest in HPV negative cancers (RR 9, P <0.01). In 
contrast, two similarly-sized mixed studies found Ku70 mRNA levels and protein 
overexpression improved recurrence-free survival in locally-advanced HNSCC [105] 
and tonsillar cancer [157], however these did not stratify for p16 status and had 
unusual treatment regimens. In support of these findings are in-vitro studies showing 
that Ku70 loss improved radioresistance in late G2/S, possibly by allowing the more 
error-free HR [145].  
(iii) Poly(ADP-Ribose) Polymerase 1 and 2 (PARP1/2) 
PARP1 and 2 have direct affinity for many DNA lesions, and once bound 
autocatalyze generation of a PAR polymer which induces chromatin decondensation 
and recruits many other repair molecules, including ATM [158]. Although it has no 
direct repair role, it is required for efficient BER, NER, HR and B-NHEJ [158-161], 
with the most well-understood role of SSB binding to facilitate polymerisation and 
ligation. PARP1 detects and flags DNA „nicks‟, often as an intermediary step of other 
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pathways, and PARP knockdown increases nick-induced HR or alternative NHEJ in 
the absence of effective HR [162]. Importantly, PARP inhibition has been found to be 
synthetically lethal in breast cancer with an innate BRCA (HR) deficiency [163, 164]. 
PARP inhibition has shown synthetic lethality with EGFR inhibitors in-vitro [165] , 
PI3K upstream inhibition [166] and induced HR defect by direct inhibition of many 
key HR mediators [167] suggesting that this is a HR related effect rather than 
specific to BRCA1. There is limited data in HNSCC cell lines that link PARP 
overexpression to cisplatin resistance [168].  
(iv) Significance 
 Ku70/Ku80 allow efficient D-NHEJ and inhibit both the more chromosomally-
unstable PARP-mediated alternative NHEJ pathway and the more error-free 
HR pathway. Previous studies have shown conflicting prognostic significance 
and unusual treatment regimens. 
 PARP has a role in repair pathway choice and scaffolding repair proteins. 
PARP-inhibition induces synthetic lethality in the presence of an additional HR 
defect, most notably BRCA1-mutated breast cancer. 
Section 2.04 Homologous recombination (HR) 
HR is a faithful repair mechanism that operates in late G2-S phase, as it requires a 
sister chromatid with homologous sequence to generate the missing nucleotides on 
the damaged strand. It is characterised by the invasion of the processed 3‟ end of 
the damaged chromatid into the homologous sequence of the sister chromatid, 
which acts as a template for repair [169]. While this is a robust system in the 
presence of an isolated lesion, it can cause loss of heterozygosity (LOH) by 
replacing wild-type genes with defective alleles in dysregulated states such as 
cancer. Following detection and end processing by MRN, there are three steps; 
strand invasion, branch migration and Holliday junction intermediate, which involves 
Rad51, Rad54, Rad55, Rad57, BRCA1 and BRCA2, Mus81/MMS4 and BLM (Figure 
2.04-2).
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Figure 2.04-2 – Homologous recombination cascade and final repair patterns; non-crossover dHR shown on right and half-crossover break-induced replication 
shown on left with loss-of-heterozygosity [141, 142, 170-172]. 
 
 
25 
 
(i) hSSB1/2 
HR requires long strands of ssDNA, which are generated by BRCA1-CtIP [139]. 
ssDNA is structurally unstable in its free unbound form. Free ssDNA generated 
normally from a replication fork is bound by RPA, which protects and induces ATR-
ATRIP signalling under conditions of replication stress and is required for BRCA1-
PALB2, and subsequent Rad51 binding [173-176]. In HR, hSSB1 and hSSB2 have 
been found to have a similar essential role in a feed-forward ATM-dependent 
manner [177, 178] through ATM and Rad51 recruitment via INTS3-C9orf80-hSSB1 
heterotrimeric complex formation [179]. In addition to its role following end resection, 
hSSB1 is also recruited directly to DSB sites and promotes MRN complex formation 
[178]. This complex has been termed sensor of single-stranded DNA complex 
(SOSS1/2)[180]. hSSB1 is also required for IR-induced G1/S and G2/M cell cycle 
arrest [177], with prevention of ubiquitin-mediated degradation of p21 likely to be the 
principal mechanism [181]. 
(ii) BRCA1/2 
BRCA1 and 2 are essential for efficient HR, and germline mutation is strongly linked 
to breast and ovarian cancer [182, 183]. BRCA1 also localizes in a BBR complex 
(BRCA1-BRCC36-RAP80) which binds ubiquitinated H2AX to inhibit HR [139, 184], 
and as mentioned BRCA1 can be functionally replaced by RNF8 in the absence of 
53BP1[143]. An interesting pattern in tongue SCC pathogenesis shows BRCA1 
overexpression in leukoplakia followed by subsequent underexpression in carcinoma 
[185]. Low BRCA expression has been correlated with better cisplatin response and 
survival in lung cancer [186], and BRCA-deficient breast cancer has shown survival 
benefit with synthetically-lethal PARP inhibition in Phase II trials [187]. Both de-novo 
mutation and promoter hypermethylation of BRCA2 are rare in HNSCC [188, 189]. 
(iii) Significance 
 hSSB1 and hSSB2 are required for efficient HR and DSB repair.  
 BRCA1 and BRCA2 are required for efficient HR. There is some evidence of 
BRCA1 downregulation in tongue SCC. 
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 Rad51 and Rad54 are essential for strand invasion and Holliday junction 
formation.  
(b) Nucleotide excision repair (NER) pathway and cisplatin resistance 
The nucleotide excision pathway (NER) corrects 'bulky' DNA adducts and lesions 
such as UV photoproducts, platinum lesions, and tobacco-linked lesions [190]. There 
are two principal monitoring pathways, global genomic-NER (GG-NER) and 
transcription-coupled NER (TC-NER).  
GG-NER is initiated by direct recognition of DNA lesions irrespective of transcription, 
and is shown in Appendix E [1, 2]. TC-NER differs in that detection and recruitment 
of repair molecules is initiated by stalled RNA polymerase II (RNAP II), with repair 
mediated by UVSSA-USP7 and BRCA [191, 192]. There is lack of a clear 
association with a cancer syndrome, in-vitro or de-novo cancers make this pathway 
a less promising factor in cancer genome stability [193, 194]. 
ERCC1-XPF has been extensively studied in lung cancer, breast cancer and 
HNSCC. High ERCC1 expression in HNSCC has been associated with cisplatin 
resistance and poor survival in a betel chewing endemic area (See Figure 
2.04-3)[130], and two larger retrospective trials showed prognostic benefit to low 
ERCC1 expression in HNSCC (HR 0.42, CI95%  0.20--0.90, p 0.03 and HR 0.12, p 
0.043), although with few oral SCC [102, 195]. In-vivo ERCC1 has been associated 
with enhanced cisplatin resistance [196] and is involved in B-NHEJ [197] .  
SNPs in all eight major NER genes have been implicated in increasing background 
risk of oral leukoplakia [198], and altered PBL expression of ERCC1, ERCC5, 
ERCC6/CSB [199] and ERCC4 [200] have been found to be higher in patients with 
oral cancer, suggesting underlying deficiencies in this pathway could be a risk factor 
for tumourigenesis.  
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Figure 2.04-3 - Kaplan-Meier chart showing progression in HNSCC treated with cisplatin, by ERCC1 
expression status [130] 
(c) MyRIP, SASH1 and BanF1 
MyRIP, SASH1 and BanF1, while identified previously as candidate tumour 
suppressor genes, are currently under active investigation as co-regulated 
components of the HR cascade linked to hSSB1 and hSSB2 by the Richard group 
(Translational Research Institute) (unpublished). 
MyRIP is a protein that was initially discovered to be involved in exosome transport 
(prototypically in melanocytes). There is emerging evidence that it is a core part of 
HR, and that exosome transport of products of HR for protease degradation is linked 
to and required for efficient repair (unpublished). 
SAM and SH3 domain containing 1 (SASH1) is a tumour suppressor gene 
downregulated in up to 74% of breast and colon cancer [201, 202], which when 
inactivated has been found to significantly weaken cell-matrix adhesion and possibly 
potentiate invasion and migration in these and osteosarcoma cell lines [203, 204]. 
Barrier to autointegration factor 1 (BAF/BanF1) is a protein implicated in Néstor–
Guillermo progeroid syndrome [205]. BanF1 localises to the nuclear membrane [206] 
and is involved in chromatin condensation and nuclear lamina assembly [207, 208], 
cell cycle progression [209]. More recently it has been found to have a direct role in 
genomic stability, via sister chromatid decatenation following DNA replication [210]. 
BanF1 is highly mobile, and while normally localised at the nuclear membrane this 
localisation is reinforced under conditions of heat stress or caloric stress via protein 
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immobilisation [211]. Interestingly, a recent study has shown a possible role for 
BanF1 in keratinocyte differentiation in psoriatic lesions [212]. The same series also 
demonstrated two distinct localisation patterns linked to keratinocyte differentiation, 
nuclear-membrane and cytoplasmic, which is also seen in our series below. 
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Chapter 3. Methodology 
Section 3.01 Study population 
The project is a cohort study of sixty-five (65) patients from the Princess Alexandra 
Hospital with sufficient stored tissue, adequate documented follow-up and correct 
primary malignancy site. Eligibility criteria included 
 Primary oral cavity cancer 
 T1 to T4 (Tx and T0 excluded) 
 N0 to N3 
 M0 (M1 excluded) 
 Modalities included; 
o Surgery alone 
o Primary radiotherapy/chemoradiotherapy 
o Surgery plus adjuvant radiotherapy/chemoradiotherapy 
Patients were included if they were treated with primary curative intent, and excluded 
if the recommended treatment was palliative. 
An initial list of 162 patients was generated from an automated electronic records 
search, and physical records were recalled. On chart review, patients were excluded 
on the basis of inappropriate site, most commonly base of tongue and supraglottic; 
lack of documentation, inadequate follow-up or missing patient records. 88 patients 
with adequate documentation were identified, and stored tissue requests were 
submitted. 23 patients at this stage were found to have missing or lack of adequate 
stored tissue, and a further 10 patients had no identifiable tumour in transposed 
cores or were lost to core processing and were excluded.  
Patients were initially selected for enrolment from Jan 2006 to August 2011. Suitable 
patients were identified from interrogation of the AUSLAB  database codes between 
these dates. 
Facility: "Princess Alexandra Hospital" and Anatomical Site: "tongue" OR 
"floor of mouth" OR "buccal" OR "oral" and Report:"carcinoma" 
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The generated report  was  manually de-duplicated and sorted. The data key 
instrument developed at the commencement of the project was revised and used to 
standardise data collection (Appendix A), for the following developments; 
 By definition, Tx or T0 tumours were not eligible as they were not clearly of 
oral cavity origin 
 N3 and M1 tumours were not treated operatively, and thus were not 
represented in the patient cohort. While N3 tumours would normally be treated 
surgically, there were no operative cases in this cohort. 
 In some cases tissue was available only for a 'recurrence' or second primary 
rather than the index case; an additional category of "Primary" for the 
"Recurrence" variable was included to indicate this. 
 "Metachronous" was removed as a histological parameter 
 "Previous" was added to variable "Neck dissection" to include those patients 
who had already had a neck dissection at the time of diagnosis. 
 
Section 3.02 Ethical and governance authorisation 
Ethical approval and Site-specific approval (SSA) was obtained through the Metro 
South Human Research Ethics Committee (Princess Alexandra Hospital) 
(HREC/13/QPAH/2). Central pathological custodian approval was also obtained 
(CaSS). 
This project requires access to identified patient data where no specific consent has 
been obtained for disclosure. Access in these circumstances is regulated under the 
Public Health Act (2005), and approval was obtained from the Director-General of 
Queensland Health (RD004675).  
(a) Chart Review 
Charts were requested and reviewed for exclusion criteria before proceeding with 
data collection. Patients were excluded for inadequate documentation (loss to follow-
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up or move to unspecified facility), inappropriate site or missing chart volumes. Many 
patients with a base-of-tongue primary site (captured with the above search terms) 
were excluded at this stage. 
Information was transcribed according to the revised data key instrument. Limited 
recurrence/mortality data was available, however consistency of reporting recurrence 
was poor and loss-to-facility follow-up was high. Relatively few recurrences were 
explicitly delineated from second primary on clinical suspicion. Comorbidity data was 
scored according to the ACE-27 system (Appendix B). 
Consistency and access to pathological reports was excellent. All reports were 
available electronically (via AUSLAB). Specimen codes were obtained for recall, and 
target tissue blocks were selected based on likely carcinoma content in cut-up 
documentation. Pathological metrics were recorded according to the revised data 
key. 
(b) Mortality data 
Overall survival (OS) data was obtained via the Queensland Cancer Registry. This 
Registry captures mortality data for all patients with a cancer diagnosis where the 
death certificate is issued in Queensland, and is independent of hospital records. 
Matched patient data was submitted for linking, and returned records were manually 
cross-checked for validity. 
 
(c) Tissue Microarray 
Retrieved archival blocks were catalogued and stored at 4°C. These were sectioned 
and H&E stains were performed. The student in conjunction with a clinical 
pathologist (DL) highlighted tumour-rich areas for TMA site selection.  
A tissue microarray was constructed from tumour-yielding blocks with a Beecher™ 
MTA-1 manual microarrayer with a 0.6mm diameter punch (UQCCR). Three (3) 
cores per patient were obtained where there was sufficient tissue, with one (1) core 
from biopsy blocks with scant tissue.  The primary TMA of 50 patients was 
constructed by the student, and stored at 4°C. A smaller accessory TMA of an 
additional 15 patients was constructed by the student. Construction was split in this 
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way to facilitate parallel grading and scoring while late tissue blocks were being 
received. 
A master map file was created, with planned cores added prior to a construction 
sequence. The microarray was batch constructed manually according to identified 
tumour sites. During construction, 'failed' cores were indicated on the map, and the 
master updated. While initial plans to obtain a „control‟ core of adjacent non-tumour 
epithelium were not successful given the heavy field dysplasia and reactive change 
present, this did not affect inter-tumour statistical analysis. 
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The primary TMA of 50 patients was constructed over a period of two months, and 
stored at 4°C. A smaller accessory TMA was constructed of an additional 15 patients 
for a total of 201 cores. 
(d) Immunohistochemical staining 
Staining was performed with the assistance of the Scientific Services infrastructure 
at QIMR Berghofer. Coarse optimisation was performed with template tissue blocks, 
then with the smaller optimisation oral cancer TMA. Optimisation protocols are 
attached in Appendix B. Existing optimisation protocols were available for most 
antibodies and were used as a baseline; significant parameter changes were needed 
for six antibodies. Successful immunohistochemical retrieval was obtained for the 
following markers; 
 hSSB1 
o Commercial hSSB1 antibody (Beryl Laboratories) demonstrated 
nonspecific stain avidity and no null cores. Subsequent staining with 
validated in-house sheep serum hSSB1 antibody proved successful. 
 BanF1 
Figure 3.02-4 – Interim progress 
tissue microarray 
Figure 3.02-5 - Beecher MTA-1 Manual Arrayer 
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 RNF8 
 Ogg1 
 PARP1 
 Ku70 
 ATM 
Attempted markers which failed to show meaningful stain differentiation 
 53BP1 (homogenous staining; included in discussion) 
 MyRIP (no stain uptake; excluded from study) 
 BRCA1 (technical problems; unable to optimise. Excluded from study) 
o BRCA1 antibody optimisation was not possible due to a lack of known 
control tissue. The standard control tissue for this antibody is BRCA1-
positive breast tissue, which was not able to be sourced. 
 SASH1 (excluded from study) 
o SASH1 antibody was not able to stain either known controls or tongue 
tissue. This was attributable to antibody failure. 
 (Ser139) γh2AX (excluded from study) 
o This antibody did not bind to any of our samples. This histone variant is 
known to be short-lived. 
 Rad51 (excluded from study) 
o Rad51 antibody did not show affinity for any tumour in the control 
blocks (including known positive controls) or the tongue optimisation 
blocks. This was attributable to antibody failure. 
Antibodies and incubation protocols are listed below and in Appendix D. Positive 
controls were obtained with standardised institutional tumour arrays from a variety of 
anatomical subsites. Negative controls were, where possible, normal tongue 
epithelial sections. 
A generalised scoring system is used, with adaptations as needed for antibody-
specific features. E.g. BanF1 shows no cell membrane localisation on any cores, and 
there are only one discrete population of cells per core; therefore these categories 
are not scored. Cellularity is used as a metric for relative usefulness of a core if there 
is disagreement between cores from the same tissue. 
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Feature Scoring 
Intensity 0 (None) 
1 (Mild uptake) 
2 (Moderate uptake) 
3 (Significant uptake) 
Localisation CM (Cell membrane) 
N (Nucleus) 
C (Cytoplasm) 
B (Nucleus & Cytoplasm) 
Cellularity 
(Amount of epithelial/tumour cells 
compared with connective tissue & 
inflammatory cells) 
0 (No tumour/unhelpful) 
1 (Occasional tumour cells or small nest; 1-
33%) 
2 (Moderate amount of useful cells; 33-66%) 
3 (Significant amount of useful cells; 66-
100%) 
Heterogeneity 
(Whether different populations of cells 
exist) 
0 (No heterogeneity) 
1-3 (Number of discrete populations) 
 Above scoring is done for each 
population as needed 
Control 0 (Tumour/highly dysplastic) 
1 (Morphologically good control) 
 
 
(e) Statistical analysis 
Data analysis is performed with the assistance of IBM SPSS (ver 21) statistical 
analysis software. Each biomarker is analysed on a whole-cohort basis for overall 
survival, and important identified patient subgroups are explored for additional 
power.  Kaplan-Meier survival graphs are constructed for each, and statistical 
significance is tested using the Mantel-Cox log rank. Interactions between 
biomarkers and clinical cofactors were manually tested using Pearson‟s R-test or 
Spearman correlation where appropriate.
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Section 3.03 Antibody optimisation schedule
Antibody Buffer Serum Retrieval  1° Antibody Incubation Polymer Chromogen 
hSSB1 (Sheep 
serum purified Ab) 
TBS Horse EDTA 
15'@105 
1:350 Da Vinci 
Green 
1 Hr RT Mach 3 GOAT Probe & 
HRP 
ImmPACT 
DAB 
BANF1 (Sigma 
SAB1409950) 
TBS  Sniper Citrate 
30''@125 
1:350 Da Vinci 
Green 
1 Hr RT Mach1 MsProbe & HRP Betazoid 
DAB 
RNF8 (Sigma 
HPA050731) 
TBS Sniper EDTA 
15'@105 
1:100 Da Vinci 
green 
1 Hr RT Mach 1 Universal HRP Betazoid 
DAB 
OGG1 (Abcam 
ab62826) 
TBS Horse Citrate 
5'@125 
1:50 Da Vinci 
Green 
Onite RT Mach2 Rabbit HRP ImmPACT 
DAB 
PARP1 (Sigma 
HPA045168) 
TBS Sniper EDTA 
15'@105 
1:200 Da Vinci 
green 
1 Hr RT Mach 1 Universal HRP Betazoid 
DAB 
Ku70 
(WH0002547M1 
SIGMA) 
TBS Sniper EDTA 
15'@105 
1:100 Da Vinci 
green 
1 Hr RT Mach 1 Universal HRP Betazoid 
DAB 
ATM (Millipore 
mab3806) 
TBS Sniper EDTA & 
Citrate 
1:100 Da Vinci 
Green 
1 Hr RT Mach 1 Universal HRP Betazoid 
DAB 
53BP1 (Cell 
Signalling #4937) 
TBS Sniper Citrate 
15' @ 105 
1:100 Da Vinci 
Green 
1 Hr RT Mach 1 Universal HRP Betazoid 
DAB 
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Chapter 4. Results 
Section 4.01 Patient Demographics 
Pooled patient characteristics, and idiosyncratic findings identified in the data will be 
discussed in this chapter. Ensuring a representative sampling of patients is essential 
for statistical validity. This is influenced by disease prevalence and aetiology 
demographics, institutional biases, tissue storage and access, and the inherent 
sample loss in the tissue microarray process.   
As discussed, oral cavity cancer is a male-predominant disease which is reflected in 
the collected data (Figure 4.01-1). Mean age at diagnosis was 67 years, with an 
asymmetrical distribution of highest frequency 
between 60 and 80 years of age.  
Smoking and alcohol habits were recorded 
from recalled clinic notes. The semi-structured 
format of the long-running PA Head & Neck 
multidisciplinary meeting made this data highly 
recordable, with the expected high smoking 
prevalence in this demographic.   
Comorbidity was consistent with previously 
published demographic data [77]. Potential bias 
includes the exclusion of primary palliative 
patients from the dataset, which would be 
expected to contain a high proportion of heavily 
comorbid patients.  
Tumour stage and nodal stage showed a 
preference toward T2+ disease. This may reflect 
the institutional referral bias at this centre, as 
early disease resectable in a satellite facility will 
Figure 4.01-1 - Sex and age distribution in 
patient data 
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be less likely to require tertiary referral.  Overall mortality in the early disease group 
(T1/2 and N0) is also expectedly low (1 of 24 patients within 18 month census, 
4.2%).  
 
(a) Radiotherapy and chemotherapy 
Radiotherapy treatment data was recorded as delivered. While in current standard 
clinical practice this is recommended on the basis of disease stage, there were a 
number of late-stage patients who did not receive adjuvant radiotherapy.  Most 
cases were in patients who had previously had radiotherapy in this area and were 
unable to receive further radiation. For these patients the index tumour used in the 
microarray was either a suspected recurrence (3 patients) or a second primary (2 
patients). Patient refusal or failure to attend accounted for two (2) cases, while one 
patient died prior to surgery or radiotherapy. Where available, all delivered 
radiotherapy regimens were of 60 or 66 Gy with no altered fractionation. 
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As discussed later, this group exhibits 
significantly different biomarker-
dependent survival  to patients who did 
receive radiotherapy. The significance of 
these results is discussed further in 
Chapter 4 (Discussion). 
Consistent with local institutional practice, 
there were relatively few patients who 
underwent chemotherapy. This was 
universally cisplatin, with no patients in this cohort treated with newer selective 
agents.  
Figure 4.01-2 - N-stage distribution of patients who 
did not receive radiotherapy 
Figure 4.01-3 - T-stage distribution of patients who 
did not receive radiotherapy 
 
 
40 
 
Demographic  N 
Sex Male 37 (67.3%) 
 Female 18 (32.7%) 
Age  Average 67 (39.6 to 92.8, see histogram 
below) 
Smoking 
Background 
Never-smoker 
Mild-Moderate (<10 
packyears) 
Heavy (>10 packyears) 
16 (29.1%) 
4 (7.3%) 
35 (63.6%) 
Alcohol 
Background 
Never/Minimal 
Light alcohol intake (~2 or 
less standard drinks/day) 
Heavy alcohol intake (~3 or 
more standard drinks/day) 
13 (23.6%) 
17 (30.9%) 
 
25 (45.5%) 
Comorbidity 
Score (ACE-
27) 
0 
1 
2 
3 
21 (38.2%) 
19 (34.5%) 
11 (20.0%) 
4 (7.3%) 
Tumour stage 
– T 
T1 
T2 
T3 
T4 
11 (20.0%) 
24 (43.6%) 
5 (9.1%) 
15 (27.3%) 
Tumour Stage 
– N 
N0 
N1 
N2a/b 
29 (52.7%) 
14 (25.5%) 
12 (21.8%) 
Treatment 
Modality 
Surgery 
Surgery & adjuvant 
radiotherapy +/- 
chemotherapy 
Definitive radiotherapy +/- 
chemotherapy 
23 (41.8%) 
30 (54.5%) 
 
 
2 (3.6%) 
Chemotherapy None 
Concurrent 
47 (85.5%) 
8 (14.5%) 
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Histological 
Parameter 
 N 
Tumour 
Thickness 
 Avg 12.6mm (0.75 to 50) 
Tumour Grade Well Differentiated 
Moderately Differentiated 
Poorly Differentiated 
Not Applicable/Not 
Reported 
6 (10.3%) 
30 (51.7%) 
18 (33.3%) 
4 (6.9%) 
Lymphovascular 
Invasion 
Not Present 
Present 
Not Applicable/Not 
Reported 
38 (65.5%) 
14 (24.1%) 
6 (10.3%) 
Perineural 
Invasion 
Not Present 
Present 
Not Applicable /Reported 
33 (56.9%) 
19 (32.8%) 
6 (10.3%) 
Nodal 
Extracapsular 
Spread 
Not Present 
Present 
Not Applicable /Reported 
43 (74.1%) 
7 (12.1%) 
8 (13.8%) 
Excisional 
Margin 
Involvement 
Clear 
Close 
Involved 
Not Applicable /Reported 
20 (36.4%) 
23 (41.8%) 
9 (16.4%) 
3  (5.5%) 
Neck Dissection Yes 
No 
45 (81.8%) 
10 (18.2%) 
Nodal Yield  Avg 34.7 (4 to 90, N = 44) 
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Figure 4.01-4 - Low mortality in early stage disease  
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Section 4.02 ATM results summary 
The DDR is principally mediated by two phosphatidylinositol 3-kinase-related kinases 
(PIKKs), ataxia-telangectasia mutated (ATM) and ataxia- and Rad3-related (ATR). 
ATM is the critical upstream regulator for the dsDNA break repair by direct binding of 
double-strand DNA free ends. We assess it here as a nonspecific marker for dsDNA 
repair activity and to probe for correlates with other downstream repair markers. 
ATM sustained the most core attrition with 23% of patients who did not have an 
interpretable tumour core, as it was the last stain to be performed. This, 
unfortunately, significantly limited the power of survival and interaction analysis. ATM 
exhibited three distinct stain localisation patterns: diffuse (cytosol) (Figure 4.02-1), 
diffuse + cell membrane (Figure 4.02-2) and a strong nuclear histotype (Figure 
4.02-3). While not reaching significance, trends suggested an association with 
poorer survival and a nuclear/cell membrane localisation (Figure 4.02-5). Stain 
intensity was not significantly associated with mortality (Figure 4.02-4), although 
trends were similar to localisation. Correlation between expression score and 
localisation was not able to be properly assessed due to low numbers, and did not 
reach significance (Table 4.02-1). 
 
 
Figure 4.02-1 - Sample tumour core showing ATM-positive cells with cytosol staining pattern 
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Figure 4.02-2 - Sample tumour core showing ATM-positive cells with cytosol and cell-membrane staining 
pattern 
 
 
Figure 4.02-3- Sample tumour core showing ATM-positive cells with nuclear-predominant staining pattern 
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Figure 4.02-4 - Whole-cohort survival graph for ATM expression score (NS) 
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Figure 4.02-5 - Whole-cohort survival graph for ATM localisation pattern (NS) 
 
 
Table 4.02-1 - Correlation between ATM expression score and localisation (NS) 
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Section 4.03 hSSB1 results summary 
The central role of hSSB1 in DSBR and genomic stability has been firmly established 
[177, 178]. This protein acts similarly to RPA in binding to exposed ssDNA strands, 
however while RPA is recruited primarily in regular DNA synthesis, hSSB1 binding of 
free ssDNA at dsDNA break sites is important to effect HR repair. 
Expression levels were high generally, and localisation fell into two distinct patterns; 
nuclear predominant (Figure 4.03-5) and nuclear + cytoplasmic expression (Figure 
4.03-4). Although most tumours expressed hSSB1, intertumour intensity was highly 
variable. In the context of high background hSSB1 expression, we chose to ascribe 
positivity where there was >75% expression among tumour cells. 
Tumour intensity scoring showed a 75.5% positivity frequency in this cohort. Overall 
survival was not significantly different between groups (Figure 4.03-1). hSSB1 
scoring suggested association with ATM intensity (Figure 4.03-2) however this did 
not reach significance and no other significant marker associations were identified. 
hSSB1 score was significantly associated with the presence of lymphovascular 
invasion (Pearson‟s R = 0.011), with no hSSB1-negative tumours (0 of 12) exhibiting 
this behaviour compared with 37.8% (14 of 37) hSSB1-positive tumours. There was 
no association between either hSSB1 intensity or localisation and any other standard 
histological parameters. 
Nuclear + cytoplasmic expression was seen in 81% of cases, and there was no 
apparent concordance between localisation and intensity scoring (Table 4.03-2). On 
whole-cohort analysis, there was also no statistically significant survival curve 
between localisation subtypes, however on subgroup analysis among patients with 
clear margins a larger significant survival benefit was found in patients with 
cytoplasmic + nuclear localisation (Figure 4.03-7), which is discussed in detail later in 
this chapter. This was independent of radiotherapy status or tumour grade. 
Characteristics of this population are listed in Table 4.03-3. 
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Figure 4.03-1 - Whole-cohort survival graph for hSSB1 intensity (Mantel-Cox log rank = 0.601) 
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Figure 4.03-3 - Sample negative hSSB1 tumour core 
Figure 4.03-2 - Association between hSSB1 intensity and ATM intensity (Pearson’s R = 0.083) 
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Figure 4.03-4 - Sample positive hSSB1 tumour core with nuclear and cytoplasmic localisation 
 
Figure 4.03-5 - Sample positive hSSB1 tumour core with nuclear-predominant localisation 
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Figure 4.03-6 - Whole-cohort survival graph for hSSB1 localisation (Mantel-Cox log rank 0.396) 
Figure 4.03-7 - Subgroup survival graph for hSSB1 localisation among patients with clear (>5mm) 
excision margins (Mantel-Cox log rank = 0.003) 
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Table 4.03-3 - Radiotherapy, T-stage and N-stage data for cohort subgroup 
with clear (>5mm) margins. 
Table 4.03-2 - Concordance of hSSB1 localisation with intensity score 
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Section 4.04 BanF1 results summary 
BanF1 is emerging as a critical mediator of chromatin condensation and is co-
regulated with hSSB1. BanF1 normally localises to the nuclear membrane, and is the 
causative mutation identified in the rare Néstor–Guillermo progeroid syndrome as 
well as local dysregulation in psoriatic lesions, however the specific biochemical 
interactions with the established DNA repair cascade have not yet been shown. We 
assess expression here as a potential novel chaperone protein in dsDNA break 
repair and for association with established DNA repair protein expression. 
BanF1 expression levels were similarly high overall with 32 of 54 (59.3%) of tumours 
graded „positive‟. Localisation was universally to the nuclear membrane, consistent 
with previous published studies on the role of BanF1, however a subgroup of 
tumours also exhibited pan-cellular/extranuclear localisation (31.5%) (Figure 4.04-2).  
BanF1 scoring did not affect prognosis in the whole cohort (Figure 4.04-5). High 
BanF1 intensity was associated with hSSB1 intensity (p = 0.006), extranuclear 
PARP1 localisation (p = 0.033) and RNF8 score (p = 0.034). This is consistent with 
the known association of BanF1 with PARP1 [213]. However, BanF1 is also an 
epigenetic regulator via its role in chromatin decondensation and nuclear lamina 
assembly [214] and may indirectly affect transcription of these markers. 
Association with ATM was mixed. While extranuclear BanF1 localisation was closely 
associated with ATM intensity (p = 0.019) (Figure 4.04-6), there was no relationship 
with ATM localisation. In contrast, BanF1 intensity was strongly associated with 
nuclear membrane ATM localisation (p = 0.016).  
BanF1 localisation was highly correlated to scoring (Table 4.04-1).  Approximately 
half of the positive samples exhibited pancellular localisation, compared with only 
9.1% of negative scoring samples. Extranuclear BanF1 localisation was associated 
with extranuclear hSSB1 localisation (p = 0.033), in addition to RNF8 score (p = 
0.046). Neither BanF1 score nor localisation were associated with any standard 
histological parameters. 
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Figure 4.04-1 - Sample negative BanF1 tumour core 
 
Figure 4.04-2- Sample positive BanF1 tumour core with nuclear membrane and cytoplasmic localisation 
 
Figure 4.04-3 - Sample positive BanF1 tumour core with nuclear membrane localisation only. 
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Figure 4.04-4 - Whole-cohort survival graph for BanF1 localisation (Mantel-Cox log rank = 0.299) 
 
Figure 4.04-5 - Whole-cohort survival graph for BanF1 intensity score (log rank p = 0.634) 
 
 
 
 
56 
 
 
Table 4.04-1 - Concordance of BanF1 scoring with localisation 
 
 
Figure 4.04-6 – Association between BanF1 nuclear localisation and low ATM expression. 
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Section 4.05 RNF8 results summary 
E3 ubiquitin-protein ligase RNF8 is primarily known for ubiquitin-chain polymerisation 
of H2A and H2Ax to promote initiation of the both HR and NHEJ upstream 
mediators. Additional roles have been recently uncovered, in particular rescuing HR 
in a BRCA1, 53BP1-deficient model, which may have implications for PARP-inhibitor 
resistance. We investigate RNF8 expression here for prognostic impact and 
correlation with HR-deficient expression patterns. 
Staining intensity showed reasonable variability with the RNF8 antibody, with 16 of 
53 valid tumours (30.2%) graded „positive‟ on stain intensity. Localisation was 
homogenous, with a granular nuclear stain uptake.  
Whole-cohort survival curves did not show significant variation with positivity. 
Similarly to hSSB1 and BanF1, prognostic differentiation was magnified in subgroup 
analysis. Patients who did not receive radiotherapy showed a significant survival 
advantage in RNF8 negative disease (Figure 4.05-4), while an inverse relationship is 
suggested but not statistically significant among the radiotherapy-treated group 
(Figure 4.05-5). Addition of RNF8 to the hSSB1/BanF1 compound marker discussed 
previously improved prognostic differentiation (Figure 4.05-6).  
Analysis of the independence of RNF8 status is complicated by correlation with 
several histological and staging parameters of aggressive disease. Association 
analysis revealed a significant association between RNF8 positivity and N-stage 
(Table 4.05-2, Figure 4.05-7), the presence of nodal extracapsular spread (Table 
4.05-1) and tumour thickness (Figure 4.05-8). 
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Figure 4.05-1 - Sample histology of positive RNF8 tumour 
 
 
Figure 4.05-2 - Sample histology of negative RNF8 tumour 
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Figure 4.05-3 - Whole-cohort survival graph for RNF8 intensity grade (Mantel-Cox log rank 0.576) 
 
Figure 4.05-4 - Subgroup survival graph for RNF8 score in patients who did not receive radiotherapy 
(Mantel-Cox log rank = 0.018) 
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Figure 4.05-5 - Subgroup survival graph for RNF8 score in patients who received radiotherapy (Mantel-
Cox log rank = 0.230) 
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Figure 4.05-6 - Subgroup survival graph of three-marker surrogate score in patients who did not receive 
radiotherapy (N = 22, Mantel-Cox log rank = 0.001); discussed further below. 
 
Table 4.05-1 - Association between RNF8 intensity and tumour extracapsular spread (Pearson’s R = 
0.007) 
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Figure 4.05-7 - Frequency chart of association between RNF8 intensity and tumour nodal stage 
 
Table 4.05-2- Association between RNF8 intensity and tumour N stage (Pearson's R = 0.036) 
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Figure 4.05-8 - Histogram demonstrating association between RNF8 intensity and tumour thickness 
(Pearson’s R = 0.021) 
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Section 4.06 Ku70 (XRCC6) results summary 
Ku70 comprises half of the Ku heterodimer by binding with Ku80. This protein 
directly binds free dsDNA ends, promotes NHEJ repair and prevents HR repair. It 
has been previously investigated in-vitro, with overexpression associated with IR-
sensitivity, however patient studies have shown inconsistent results. We assess 
expression here to explore correlation with our HR repair markers and to attempt to 
clarify previous work regarding prognostic impact. 
Ku70 uptake was overwhelmingly positive in the cohort, with only 4 of 53 tumours 
scoring negatively. Localisation was found to be of two main histotypes; strong 
nuclear uptake (Figure 4.06-1) and weak nuclear uptake (Figure 4.06-2). Positivity 
on intensity scoring was strongly associated with strong nuclear localisation (p = 
0.001) (Table 4.06-1).  
Whole cohort analysis showed no survival differences on the basis of either Ku70 
scoring or localisation (Figure 4.06-5, Figure 4.06-3). PARP1 extranuclear 
localisation was associated with Ku70 strong nuclear staining (p=0.002), and there 
was an association between heavy tobacco use and the less common weak nuclear 
uptake pattern (p = 0.040) (Figure 4.06-4). As a principle component of the NHEJ 
DNA repair process, statistical interrogation of potentially synthetically lethal 
combination markers was undertaken. These did not show significant survival 
differentiation (example given in Figure 4.06-7).  
 
Figure 4.06-1 - Sample positive Ku70 core with strong nuclear staining 
 
 
65 
 
 
Figure 4.06-2 - Sample positive Ku70 core with weak nuclear staining 
 
Figure 4.06-3  - Whole-cohort survival graph for Ku70 localisation (NS) 
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Figure 4.06-4 - Correlation of Ku70 with tobacco use (p = 0.040) 
 
 
Figure 4.06-5 - Whole cohort survival graph for Ku70 expression score (NS) 
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Table 4.06-1 - Correlation of Ku70 expression score with Ku70 localisation (Pearson's R = 0.001) 
 
 
 
Figure 4.06-6 - Whole-cohort survival graph for Ku70 and hSSB1 composite localisation score (NS) 
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Figure 4.06-7 - Correlation of Ku70 localisation with PARP1 localisation (p = 0.002) 
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Section 4.07 PARP1 
PARP1 is essential for repair of ssDNA lesions, which are an intermediate step for 
base-excision repair and nucleotide-excision repair pathways. Unrepaired ssDNA 
lesions progress to dsDNA lesions when encountered by a replication fork. This has 
been successfully exploited in BRCA1-deficient breast cancer, where PARP-inhibitor 
therapy improves radiosensitivity by possibly accelerating the generation of dsDNA 
breaks in the context of pathologically ineffective HR. The principle of synthetic 
lethality may be translated to any HR-deficiency. We assess tumour PARP1 
expression prevalence here to explore utility of PARP1 inhibition in combination with 
our other project biomarkers and to investigate correlates. 
PARP1 expression was scored high in the majority of tumours (88.5%), and 
localisation fell into either a predominant nuclear & chromatin pattern (86.2%) 
(Figure 4.07-1) or nuclear –only (13.8%) (Figure 4.07-2). 
Whole cohort analysis showed no prognostic difference with PARP1 score or 
localisation (Figure 4.07-3, Figure 4.07-4), and were strongly correlated (Table 
4.07-1). Low hSSB1 and PARP1 expression was a particularly rare combination, 
with only 2 patients exhibiting this pattern. Interestingly, PARP1 nuclear localisation 
was strongly associated with heavy tobacco exposure (Figure 4.07-5). Perineural 
invasion was associated with the nuclear and chromatin localisation pattern 
(p=0.049), and was not present in any nuclear-localised tumours. Similarly there was 
a suggested association with lymphovascular invasion, with no nuclear-localised 
tumours exhibiting this pattern, however this did not reach significance (p = 0.087) as 
the majority of “nuclear & chromatin” localised tumours also did not show this 
feature. Nuclear-only PARP localisation was also associated with a smaller tumour 
thickness (Figure 4.07-6). 
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Figure 4.07-1 - Sample positive core with a nuclear and chromatin localisation pattern 
 
Figure 4.07-2 - Sample positive core with a nuclear-only localisation pattern 
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Figure 4.07-3 - Whole-cohort survival graph for PARP1 expression score (NS)
 
Figure 4.07-4 - Whole-cohort survival graph for PARP1 localisation (NS) 
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Table 4.07-1 - Correlation between PARP1 localisation and score (p = 0.000) 
 
Figure 4.07-5 – Correlation between PARP1 localisation pattern and tobacco use (p = 0.026) 
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Table 4.07-2 - Correlation of PARP1 expression score with perineural invasion (p = 0.049) 
 
 
Figure 4.07-6 - Correlation of tumour thickness with PARP1 localisation pattern (Levene's test trimmed 
mean p = 0.039) 
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Section 4.08 Ogg1 results summary 
Ogg1 is a protein in the base-excision repair pathway, and is specifically involved in 
the repair of 8-oxoguanine (8-oxo G) DNA lesions. The 8-oxo G lesion is 
characteristic of benzo-[a]-pyrene tobacco-exposure associated DNA damage, and 
unrepaired will progress to a dsDNA break.  
Ogg1 exhibited approximately even discrimination in the cohort, with 52% 
demonstrating positive (high) expression (Figure 4.08-1, Figure 4.08-2). Localisation 
was comparable, with positive tumours showing granular nuclear expression (Figure 
4.08-1).  
There was no difference in overall survival with Ogg1 expression (Figure 4.08-3). 
There was a suggestion of an Ogg1-negative disease disposition in patients who did 
not consume alcohol, although this did not reach significance (p = 0.066)(Figure 
4.08-4). Ogg1 positivity was highly correlated with RNF8-negative expression 
(p=0.001) (Figure 4.08-5). Lymphovascular invasion was also found to be correlated 
with Ogg1 positivity (p = 0.046). 
 
 
 
Figure 4.08-1 - Sample tumour core with positive Ogg1 expression 
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Figure 4.08-2 - Sample tumour core with negative Ogg1 expression 
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Figure 4.08-3 - Whole-cohort survival graph for Ogg1 expression score (NS)
 
Figure 4.08-4 - Association between Ogg1 expression score and alcohol exposure (NS) 
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Figure 4.08-5 - Correlation of Ogg1 expression score with RNF8 expression score (p = 0.001) 
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Section 4.09 γH2Ax, Rad51 and 53BP1 
The markers γH2Ax, Rad51 and 53BP1 did not show inter-tumour stain variation. 
γH2Ax is a histone variant (H2A) specifically phosphorylated at Serine 139 in 
response to a dsDNA break. This is a rapid and expansive process, making it an 
attractive marker for dsDNA activity in-vitro; however it is a short-lived reactive 
phosphorylation event which complicates antigen retrieval in older fixed specimens. 
γH2Ax is essential to attract and retain 53BP1, which promotes cell-cycle checkpoint 
activation and promotes non-homologous end-joining. Similarly to ATM, the intention 
of assessment of γH2Ax and 53BP1 was as a marker for the activity of the dsDNA 
break cascade. 
Rad51 is a large, multifunctional protein that is essential for repair via homologous 
recombination. It coordinates strand invasion, Holliday junction formation and 
recruitment of downstream proteins. 
Rad51 and γH2Ax showed no affinity for any cores.  
53BP1 consistently showed universal nuclear affinity in all tumour samples (Figure 
4.09-1). This was not seen in surrounding tissue, and staining intensity was 
comparable between all samples.  
 
Figure 4.09-1 – Sample tumour core showing granular nuclear 53BP1 expression 
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Section 4.10 Overall survival analysis 
Prognostic determination of overall 18 month survival is the primary project outcome. 
Within the power constraints of our limited population cohort, no markers were found 
to show statistically significant survival benefit across the entire cohort. Subgroup 
analysis suggested a number of important patient categories that demonstrated 
significant biomarker differentiation; most demonstrably in patients who did not 
receive radiotherapy. The frequency limitation of overall survival data in low-mortality 
subgroups (such as early disease) complicates analysis and decreases whole-cohort 
prognostic power.  
As discussed, there was only one death in the early-disease subgroup, which makes 
the radiotherapy-naïve survival differences seen with our biomarkers largely a 
comparison between late-stage tumour prognosis. There is also a relative 
underrepresentation of early disease in this cohort, due to the referral pattern of the 
tertiary institution that this project was conducted from. No statistically useful 
prognostic information can be ascertained from the early-disease subgroup in this 
cohort. Therefore to improve power in developing a prognostic framework, two 
primary methods are employed; 
1. Subgroup analysis in; 
a. Radiotherapy-given vs. No radiotherapy group 
b. Patients with clear excision margins vs close or involved margins, and 
2. Combination biomarkers; 
a. hSSB1 localisation and BanF1 score 
b. hSSB1 localisation, BanF1 score and RNF8 score 
(b) Radiotherapy subgroup analysis 
One of the identified important factors that discriminates the survival effect of our 
biomarkers was whether patients received radiotherapy in the course of their 
treatment. In this section, we will describe the characteristics of this subgroup and 
how it applies to clinical practice.  
As discussed previously, genomic instability is a double-edged sword; while it is the 
driving force toward accumulation of the genetic mutations that define cancer 
initiation, invasion and spread, it is also exploited upon to differentially sensitize 
tumour cells to cytotoxic therapy. For this reason, it is attractive to assess the impact 
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of genomic stability biomarkers by stratifying for the effect of radiotherapy. There are 
limitations, however, that in a retrospective cohort study the decision to offer or 
initiate radiotherapy (and therefore assign a patient to the no-radiotherapy subgroup 
in our analysis) will have been dictated by the conventional clinical parameters at the 
time of treatment. Most importantly, the local institutional treatment guidelines 
generally indicate radiotherapy for all disease of T1+ or N0+ stage. The presence, 
then, of later-stage disease in this subgroup indicates a departure from standard 
clinical practice and potentially biases interpretation.  The population characteristics 
are listed below in Appendix G. Most importantly, the most common reason for 
inclusion of late stage tumours in the “no radiotherapy” group is that they have 
previously received radiotherapy to the head and neck, and the index tumour is 
either a suspected recurrence or an unrelated second primary. This biases the 
subgroup with generally more comorbid patients.  
While subgroup selection on the basis of radiotherapy treatment is logical given the 
role of these markers, it is also a retrospective grouping which is less useful 
clinically. Allocation to this group is not on an intention-to-treat basis, as clearly late 
disease would not be appropriate. Therefore, these results are most applicable to 
patients who are unable or unwilling to receive radiotherapy as a therapeutic option, 
whether it was able to be given or not.  
In summary, the “no-radiotherapy” subgroup in our cohort is; 
 A logical stratification on a biomolecular basis, given the common IR-induced 
lesions and the role of our markers in the DNA damage repair system; 
 A retrospective grouping inclusive of patients who were not offered 
radiotherapy, or would have been offered radiotherapy but were unable to 
tolerate it, 
 Contains both early-stage patients and late-stage patients with comorbidity. 
(c) Margin Involvement 
The other major factor that impacted statistical analysis was the involvement of 
margins in the surgical resection. While factors such as tumour location, patient 
morphology and tumour size greatly affect the technical difficulty associated with 
surgical excision, the presence of involved or close margins is generally undesired. 
Margin involvement independently increases relative mortality risk, with studies 
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variably reporting relative risk from 2 to 16 times, and close margins of 5mm or less 
increases risk from 1.3 to 2.6 times [215-219]. Importantly, a clear surgical margin is 
a generally favourable factor and commonly influences clinical decision-making for 
recommendation of adjuvant treatment, and therefore is of great interest for 
biomarker-assisted refinement.  
Subgroup characteristics are shown in Appendix G. 38.5% (20 of 52) patients had 
clear margins, 41.8% (23 of 52) had close margins of less than 5mm and 16.4% (9 of 
52) had involved margins. Expectedly, there is an overrepresentation of late stage 
disease where there were close or involved margins.  
(d) hSSB1, BanF1 and RNF8 composite score predicts survival inversely 
depending on radiotherapy treatment 
In patients who did not receive radiotherapy, elevated expression of hSSB1, BanF1 
and RNF8 irrespective of localisation predicts poor survival, while in patients who 
were treated with radiation the inverse relationship is suggested.  
The hSSB1 and BanF1 composite score is given to tumours that express positivity in 
both markers. This score shows statistically significant differentiation in the no-
radiation subgroup (Figure 4.10-1). The addition of positive RNF8 expression to the 
composite score further accentuates the prognostic prediction (Figure 4.10-2). 
Interrogation for a „repair-poor‟ phenotype with triple negative markers was 
suggestive but did not achieve significance (Figure 4.10-3). 
While it is not possible to assess whether the biomarker differentiation is simply 
demarcating later stage tumours, as statistical power suffers on further stratification 
due to low numbers, the inverse survival relationship seen between the groups 
suggests that this is not the case. 
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Figure 4.10-1 - Subgroup survival graph for hSSB1/BanF1 composite score in patients who did not 
receive radiation (Mantel-Cox log rank – 0.015) 
 
Figure 4.10-2 - Subgroup survival graph for hSSB1/BanF1/RNF8 composite score in patients who were 
not treated with radiation (Mantel-Cox log rank = 0.001) 
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Figure 4.10-3 - Subgroup survival graph for hSSB1/BanF1/RNF8 negative composite score in patients 
who were treated with radiotherapy (Mantel-Cox log rank = 0.207) 
 
Figure 4.10-4 - Subgroup survival graph for hSSB1/BanF1/RNF8 composite score in patients who were 
treated with radiotherapy 
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(e) hSSB1 localisation in patients with clear surgical margins predicts survival 
In patients with clear surgical margins (>5mm), nuclear-predominant hSSB1 
localisation predicted significantly poorer survival (Figure 4.10-5).  
 
Figure 4.10-5 - Subgroup survival graph for hSSB1 localisation in patients with clear surgical margins 
(Mantel-Cox log rank = 0.003) 
In patients with involved or close margins there was no statistical significance on any 
marker. Within the clear margin subgroup shown above, radiation treatment, 
comorbidity and staging characteristics were comparable. This is statistically 
unexpected, as mortality is significantly higher by proportion with involved margins 
and similar with close margins. It is not clear whether a local or distant disease 
mechanism is associated with these treatment failures, as recurrence details were 
not able to be captured comprehensively within the limitations of the retrospective 
design. 
The clear-margin group is subject to selection bias in overrepresentation of early 
disease, and as such the nuclear-predominant localisation may represent an 
underlying aggressive phenotype. The marked survival differences in a cohort which 
has a more favourable clinical prognosis suggest that this candidate marker may be 
a useful adjunct in clinical decision making. 
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Chapter 5. Discussion 
Section 5.01 Overview and Introduction 
 
In this chapter the significant results and clinical implications of this study will be 
explored, in the context of the chosen methodology and known published 
biomolecular framework of the DNA damage repair cascade. The definitive project 
outcome metric is overall 18-month survival, the calculation of which has been 
discussed previously in Chapter 3 (Results). We have described two previously 
unreported biomarker tools to predict prognosis in selected patient subgroups. We 
discuss here how these results relate with the existing literature. The remainder of 
the chapter will be structured to examine the other inter-variable associations found 
in this study. 
The prototypical biomarkers investigated in this study that showed meaningful 
immunohistochemical differentiation were hSSB1, BanF1, NEIL1, Ogg1 and RNF8. 
Matched interrogation of closely-related DNA repair cascade markers Ku70, ATM 
and PARP1 was possible in this cohort. Planned peripheral markers 53BP1, Rad51, 
gammaH2Ax, SASH1 and MyRIP were also investigated but showed no useful 
histological uptake on staining. The challenges of implementing a retrospective 
cohort study, which will be discussed further below, complicated statistical analysis 
in some patient groups.  
Previously unreported associations were found between biomarkers Ogg1, PARP1 
and RNF8 with other clinical cofactors. Pathway mapping was explored to 
investigate phenotypes that may have exploitable synthetically lethal targets. 
Additionally, some biomarker combinations that were seen to be unusual in the wild-
type tumours are discussed for potential target identification. 
Section 5.02 Survival analysis using composite biomarkers 
One of the principal findings shown in the previous chapter were the generation of a 
survival graph from subgroup analysis with a combination of biomarkers; hSSB1, 
BanF1 and RNF8. Composite, or combination biomarkers are statistically useful 
where the individual markers improve specificity for an aggressive cancer phenotype 
in a complimentary or additive manner [220]. Composite markers have been used in 
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larger studies to improve statistical contrast [221], however this comes at the 
expense of sensitivity in a binary outcome setting.  Some challenges are involved in 
translation to clinical and regulatory implementation of composite biomarkers, most 
notably regarding the reporting and interpretation of individual markers in the 
composite score [222]. Delineating the relative contributions of hSSB1, BanF1 and 
RNF8 to overall mortality in this metric will require a substantially larger prospective 
cohort. 
 
Section 5.03 Associated findings 
A number of peripheral findings were noted in the statistical analysis of the grading 
data. The secondary thesis objective is potential identification of biomarkers that can 
select for tumours with essential or synthetically lethal molecules, as potential 
inhibitor targets. These candidates can be suggested on the basis of two findings; 
1. Unusual or non-existent expression combination may represent a unstable 
phenotype; drug targets to replicate or force these conditions may be of 
benefit, and 
2. Expression combinations associated with conventional prognostic or 
aetiological factors;  these may represent distinct aetiological disease 
phenotypes with shared pathway defects that warrant further investigation 
We found uniform nuclear expression of 53BP1 in our samples. IR-induced 
recruitment of 53BP1 is dependent upon RNF8-mediated JMJD2A domain 
degradation [136, 223], however RNF8 can also directly load the Rad51 repair 
complex and restore HR repair in BRCA1, 53BP1 deficient cells [143]. In this series, 
BRCA1 deficiency was used as a prototype for early HR-initiation, however this 
process is also dependent on effective hSSB1 recruitment [178]. We have identified 
a subset of tongue cancer with relatively high RNF8 expression in 30% of our cohort, 
which showed an apparent relative radioresistance within the aforementioned 
limitations of our no-radiotherapy subgroup. These findings suggest a role for further 
investigation of the benefit of PARP inhibitors in tongue cancer, with a 
biomechanically-based selection tool for prediction of resistance. 
Conventional histological parameters were associated with expression of PARP1 
and RNF8. Tumour thickness, an important prognostic factor that represents local 
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invasiveness, was positively associated with RNF8 expression and both extranuclear 
PARP1 localisation and an association suggested with high PARP1 expression.  
Histological 
Parameter 
RNF8 PARP1 Ogg1 
Lymphovascular 
Invasion 
No association Nuclear & Cytoplasmic 
localisation (p = 0.087) 
High (positive) 
expression (p=0.046) 
Perineural Invasion No association High (positive) 
expression  
(p = 0.049) 
 
Thickness High (positive) 
expression  
(p = 0.021) 
Nuclear & Cytoplasmic 
localisation (p = 0.039) 
 
Extracapsular 
spread 
High (positive) 
expression  
(p = 0.007) 
  
Smoking No association Nuclear localisation  
(p = 0.023) 
 
Tumour T-stage No association   
Tumour N-stage High (positive) 
expression  
(p = 0.036) 
  
 
In particular, high RNF8 expression seems associated with nodal metastasis and 
extranodal spread. As mentioned previously, oral cavity cancer has high and early 
occult metastatic rate [6], and severe (grade 4) extracapsular spread is associated 
with significantly increased locoregional recurrence and lower overall survival [217, 
224]. Biomarker-based identification of tumours with a nodal metastatic tendency at 
an early biopsy stage would be invaluable for clinical decision-making and treatment 
recommendation. It is not possible in this retrospective study to determine if this 
expression phenotype precedes nodal metastasis or is a consequence of other 
upstream mutations; a prospective prognostic study is required to determine the rate 
of subsequent nodal metastasis in RNF8-positive tumours. 
PARP1-localisation was associated strongly with smoking-related tumours, while 
tobacco lesion-specific repair molecule Ogg1 showed no association. These tumours 
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also had higher rates of small-nerve perineural invasion, a histological marker of 
invasiveness with unclear prognostic relevance [79]. PARP1 expression was highly 
prevalent in our cohort (86.8%) and was strongly associated with Ogg1 expression 
(p = 0.028). This is consistent with the in-vitro requirement of oxidative-stress 
induced Ogg1-PARP1 binding to functionally promote 8-oxoG lesion repair [225, 
226]. While constitutive expression of PARP1 is consistent with the field effect of 
tobacco exposure which underpins the aetiology of most tongue cancer, it also 
suggests a pathophysiological pathway for further investigation of PARP inhibition 
sensitivity. 
Section 5.04 Methodology discussion 
The design of this project was necessarily a nonrandomized retrospective cohort 
study. Several potential pitfalls have been identified and discussed previously. 
Specific points of difficulty encountered in the data collection phase; 
 Retrospective data collection was difficult due to non-standardised notation 
and rate of physical chart loss. While almost all charts contained the required 
information, it was often not readily available and required careful scrutiny of 
large multi-volume records for each patient. This highlights the importance 
and advantages of a standardised prospective patient data collection, 
particularly in the framework of a multi-purpose research database. 
 As our series encompassed a number of years, there was variety in the 
comprehensiveness of the pathological reports. These reports in a small 
number of patients did not include some prognostic characteristics of disease 
(i.e. extranodal spread, perineural invasion). As these characteristics are 
graded according to greatest extent, reanalysis of these tumours to provide 
these data would require access to, slide generation and reporting of the 
entirety of the patient blockset. As the stored blocks were very infrequently 
complete even this analysis could not be accurate. 
 Alcohol intake was particularly poorly-quantified in clinical notes, with 
qualifying adjectives ('minimal', 'light/moderate/heavy', etc) typically used in 
place of standard drinks per day. 
 The most consistent point-of-contacts for patient records were initial clinical 
assessment and surgical admission. Follow-up often was deferred to closer 
regional centres or patients were lost to follow-up. Where recurrence occurs, 
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particularly distant metastasis, palliative management is standard medical 
practice and re-referral to a tertiary centre is not typically required. The 
preferred end-point for prognostic studies is either recurrence-free survival or 
disease-specific survival, however this is not reliably obtainable 
retrospectively. While recurrence data when available was recorded in the 
database, the lack of documented recurrence unfortunately is not evidence of 
recurrence-free survival and this data was not used or obtainable. 
Immunohistochemical marker assessment is commonly performed in clinical 
medicine with universal familiarity among anatomical pathologists, therefore we used 
this methodology to optimally develop a clinically useful biomarker panel that would 
ideally fit into this workflow. Although this eases the translation of our results to 
clinical practice, there are several problems associated with interpretation of new, 
untested immunohistochemical results. 
There are limitations associated with pathophysiological interpretation of 
immunohistochemical scoring in our cohort; 
 Selectivity is highly antibody-dependent. Only one of our antibodies was 
selective for an activating phosphorylation domain (Ser139 gH2Ax), and 
expression levels may not correlate well with activity levels due to functional 
mutation or post-translation modifications. 
 Despite rigorous adherence to protocol, inter-block staining was variable, with 
significantly more stain uptake in the accessory TMA that likely reflected the 
relatively smaller amount of tissue. Relative expression scoring is dependent 
upon calibration between adjacent cores in the array, and comparison of 
cores from one TMA with another would yield incorrect results. 
o While a common problem with research antibodies, this finding 
signified an unexpected advantage of the tissue microarray technique; 
using conventional immunohistochemical staining with a separate slide 
for each tumour, this variation would be unable to be controlled for or 
even discovered. 
Implementation of a validated biomarker panel into clinical practice also presents a 
number of challenges; 
 Standardisation of staining between laboratories is subject to; 
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o Consistent antibody selectivity and binding 
o Strict benchmarking and consistent antigen retrieval, primary and 
secondary incubation processes 
 Standardisation of grading between pathologists is subject to; 
o Common nomenclature and uniform, unambiguous guidelines for 
scoring 
o Calibration and quality-control between institutions 
While several advantages have been cited for the tissue microarray technique 
above, some potential problems were identified; 
 Variable age of samples can affect antigenicity and can introduce temporal 
bias, tumour heterogeneity and undersampling [227-229]. 
o Fortunately in our data there was no significant association between 
sample age and antigen retrieval.  
o Although there was a slight tendency toward T1 disease later in the 
inclusion period, referral patterns did not significantly change with 
regard to staging. 
o Sampling error is unavoidable with conventional IHC, however is 
magnified in microarray analysis. Core populations could be 
misrepresentative of the tumour, or potentially miss identification of 
small aberrant populations such as cancer stem cells. For this reason, 
CSCs and subpopulations were not treated separately in grading. 
 Core loss resulted in some inconsistent data points, particularly in later slides 
as cores began to „bottom-out‟, resulting in some patients having no valid 
cores despite the in-built redundancy. Unfortunately this limits statistical 
power in some marker comparisons where there are no matching cores. The 
most significantly affected marker was ATM, with 23.6% attrition, while other 
markers had only between 0% to 5% attrition. Redundant cores for each 
patient assisted with retention for each marker. 
Section 5.05 Correlation of localisation findings with functional 
significance and previous work 
53BP1, a marker which we were unable to grade, had a remarkably consistent 
staining pattern across all tumours. A critical pathway determinant, 53BP1 loss has 
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been shown to rescue the PARP-inhibitor sensitivity seen in HR-deficient tumours 
and induce resistance to these agents [141]. While in-vitro tumour cell lines have 
shown constitutive granular nuclear expression [119], there are no larger studies that 
demonstrate this in human tumours. The homogenous granular nuclear expression 
seen in our series supports this finding in human tongue cancer. 
Physiologically BanF1 is localised to the nuclear membrane, where it is assists 
chromatin condensation and nuclear lamina assembly [206-208], and tethers 
telomeres to the nuclear periphery [230]. This nuclear localisation is normally 
reinforced under conditions of stress [211]. Our results show a tumour subpopulation 
of 31.5% with a distinct pan-cellular localisation pattern, which is consistent with 
limited previous findings in breast cancer cell lines [231].  
hSSB1 physiologically localises to ssDNA at dsDNA break sites and free telomere 
strands in the nucleus [178]. We found two distinct localisation patterns; pan-cellular 
(81%) and nuclear (19%). Interestingly we found that nuclear localisation was 
associated with a poorer outcome in subgroup analysis of patients with clear 
excision margins. While extranuclear localisation of hSSB1 and interacting subunit 
C9orf80 (SOSSB1 and SOSSC) has been shown to be associated with loss of 
INTS3 (SOSSA) in cell line knockdown studies [232], this mechanism would not be 
consistent with the prognostic findings. Dysregulated localisation of both BanF1 and 
hSSB1 was found to be associated. These findings suggest either nonspecific 
inappropriate extranuclear transport, increased nuclear membrane permeability, or 
microregional co-localisation of BanF1 and hSSB1 through their respective 
interactions with free telomere ends [233].  
Ku70 forms half of the DNA-PK heterodimer (with Ku80), and is essential for NHEJ 
repair. We found a predominantly „strong nuclear‟ expression pattern, associated 
with cytoplasmic PARP1 expression, with a small subset of cells exhibiting a weak 
nuclear pattern which was associated with a heavy smoking history. Normal Ku70 
expression is relatively high in epithelial cells, with a diffuse staining pattern [234]. A 
pre and post-treatment trial demonstrated that nuclear PARP1 overexpression in oral 
cancer is inducible following radiotherapy, however overall intensity is not predictive 
of treatment effectiveness or prognosis [235]. A larger non-subsite specific HNSCC 
study also showed an exclusively nuclear staining pattern, and while this 
demonstrated a higher disease-free survival with high Ku70 expression this was a 
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cross-site analysis with only 22% from the oral cavity [105]. A strong nuclear 
expression pattern for Ku70 was noted in colorectal carcinoma, with 20% of 
carcinoma and 55% of adenoma showing cytoplasmic staining [236]. Breast cancer 
exhibits an exclusively nuclear pattern [237]. The identification of a small cohort of 
Ku70 weak-nuclear staining tumours, associated with tobacco exposure, has not 
been previously reported. 
Limited studies of PARP1 localisation have been undertaken in oral cavity cancer; as 
part of a larger biomarker panel screen of 66 oral cavity cancers it was stated that 
there was a predominant nuclear staining [238]. This study however did not assess 
localisation patterns however and this label did not preclude incidental cytoplasmic 
staining. PARP1 localisation has been most extensively studied in breast cancer as 
an adjunct to the numerous trials of PARP1 inhibitors in triple-negative breast 
cancer. Here, again in contrast to our findings, nuclear localisation pattern is 
predominant (85%-100% of BRCA1-associated and 94% of BRCA1-non-associated 
tumours) [239, 240]. In further contrast, a well-powered prospective prognostic trial 
showed significantly increased mortality with „high‟ cytoplasmic PARP1-expression; 
however direct comparison is difficult as this study scored nuclear and cytoplasmic 
staining separately and did not assign an overall localisation pattern [241].  
Section 5.06 Formulation of a prognostic data tool and further work 
Our identified subcohorts fall into two practical clinical patient categories 
1. Patients who are unable or unwilling to be offered radiation therapy, 
irrespective of tumour stage, and; 
2. Post-operative patients with clear excision margins. 
(a) Proposed prognostic model 1 
In the first category, 18-month overall survival is influenced by a composite 
biomarker score 
 hSSB1 expression score positive 
 BanF1 expression score positive, and 
 RNF8 expression score positive 
A positive composite score indicates a significantly poorer prognosis in this group 
(OR 16.83, 95% CI 1.72 to 164.5, p = 0.015).  
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(b) Proposed prognostic model 2 
In the second category, 18-month overall survival is influenced by a single biomarker 
score; 
 hSSB1 nuclear localisation 
A nuclear localisation pattern indicates a significantly poorer prognosis in this group 
(OR 16.94, 95% CI 1.46 to 200.0, p = 0.024).  
Section 5.07 Further Work 
(a) Investigation of 53BP1-dependent PARP1 inhibitor sensitivity in RNF8-
deficient tumours 
In our cohort we found positive expression prevalence for RNF8 was 30%. As 
discussed, effective PARP1 inhibition is dependent on the presence of functional 
53BP1, otherwise the critical HR defect may be rescued by RNF8. 
To investigate if this has implications for selection of PARP1 inhibitor sensitivity, an 
explant tumour model project is proposed; 
1. Patient tumour samples are collected prospectively and cultured using an 
animal explant model, 
2. Tumours are assessed for RNF8, BRCA1, hSSB1 and 53BP1 expression 
(RNA and immunohistochemistry), 
3. IR-sensitivity is assessed in PARP1-inhibited animals and compared with 
control animals for each tumour 
4. PARP1-inhibitor efficacy is correlated with relative RNF8 and 53BP1 
expression. 
(b) PARP1 and Ogg1 expression in tobacco exposure-associated tumours 
We found a strong link between co-expression of PARP1 and Ogg1 with tobacco 
exposure. As discussed, this has a strong biochemical basis in the pathogenesis of 
tobacco-associated DNA lesions. While the majority of oral cavity cancer remains 
tobacco-associated, as discussed earlier there is an increasingly prevalent cohort of 
younger patients with aggressive disease that is not associated with tobacco 
exposure. 
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While our data does not show significant mortality differences on the basis of these 
biomarkers, the relatively small proportion of patients with this phenotype requires a 
much higher powered database. Biomarker-based differentiation of this cohort may 
be useful to determine the relative effectiveness of PARP1-inhibitors, as mentioned 
in the previous section.  
This would be best investigated with a prospective cohort design, with tumour 
biomarker profiles for PARP1 and Ogg1 correlated with tobacco exposure with a 24 
month follow-up for overall and recurrence-free survival. As the phenotype of interest 
has been reported to be associated with a younger age of onset, recurrence data is 
critical to control for bias in the more comorbid tobacco-associated cohort. This could 
be most effectively conducted in coordination with the previously-discussed project 
to additionally assess explant IR-sensitivity and PARP-inhibitor efficacy. 
Section 5.08 Final words 
Prognostic imputation in tongue cancer using clinical parameters is presently 
unreliable due to early and occult metastasis and inability to predict response to 
adjuvant treatment. Genomic instability underpins tumour pathogenesis and 
contributes to ongoing malignant characteristics. There is considerable evidence that 
disruption of DNA repair in primary tumours is associated with poor survival, 
however the nature and mechanism of this is unclear. Using a validated, high-
throughput technique, this study has proposed a prognostic tool that aims to improve 
prognostic modelling and guide treatment choice in the clinic. Several previously 
unidentified associations have been found between DNA repair components and 
conventional clinical parameters, indicating the need for further work to elaborate 
these interactions. 
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Appendix A - Relative risks and hazard ratios for clinicopathological 
variables from review of literature 
 
Risk factor Relative risk adjustment for 5-year overall survival  
(unless otherwise stated) 
T-stage 
    I 
- 
1.00 
    II 2.15 [52], 1.47 [85], 1.335 [242], HR 1.38 [84], 1.51 [79] 
    III 4.42 [52], 1.93 [85], 1.549 [242], HR 1.92 [84] 
    IV 5.21 [52], 2.36 [85], 2.03 [242], HR 2.48 [84] 
N-stage 
    0 
- 
1.00 
    I 2.25 [52], 1.365 [242], HR 1.42 [84] 
    I+ 2.15 [215] 
    II+ 5.53 [52], 2.06 [85], HR 1.94 [84] 
    III 2.84 [85], 2.395 [242], HR 2.57 [84] 
M-stage 
    I 
 
6.18 [85], 6.707 [242], HR 2.37 [84] 
Previous malignancy 1.90 [85], 1.73 [242] 
Comorbidity (ACE-27) 
    Mild 
 
NS [242], HR 1.22 [84], 0.95 [77], 1.21 [80] 
    Moderate 1.39 [242], HR 1.39 [84], 1.98 [77], 1.86 [80] 
    Severe 2.29 [242], HR 1.68 [84], 1.95 [77], 2.56 [80] 
Age 
       < 70 years old 
1.00 
       > 70 years old 2.84 [52], 2.71 [85], not generalizable [242], HR 2.35 (>65) [218] 
Nonsmoker 1.4 [52] 
Female No difference [85, 242], HR 1.59 [218] 
Positive surgical margins 15.3 [217], 11.61 [215], HR 1.9 (c.f. close & clear) [216], HR 2.5 
[218], NS [219] 
Close surgical margins  
     (<2mm) 
 
NS [217], 2.66 [215], HR 1.5 [218] 
Perineural invasion NS [79] 
Lymphovascular invasion NS [79, 217, 243], 1.32 (BVI) [244]  
Tumour depth  
      >4mm 
2.48 DFS [243] 
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Nodal Yield  
      < 18 nodes 
3.5 [245] 
Extracapsular spread 7.3 [217] 
Lymphocytic infiltrate 
absent 
HR 10.37 [246] 
Histological grade  
      - Well-differentiated 1.00 
      - Moderately-
differentiated 
2.70 (5-year OS) [52] 
      - Poorly-differentiated 4.38 (5-year OS) [52], 6.44 DFS, 22.91 OS [79], HR 4.5 [246], 
(+) [219], 3.1 [243] 
Recurrence  
      - local recurrence 3.1 [217], HR 1.55 (at 1 year)[84] 
      - regional recurrence 6.9 [217], HR 1.76 (at 1 year)[84] 
      - distal recurrence NS  [217], HR 9.37 (at 1 year)[84] 
"Radiotherapy" 4.3 (P-value 0.1) [217] 2.0 [52], HR 1.16 (c.f. surgery) [84] 
 
  
 
 
98 
 
Appendix B  - The Adult Comorbidity Evaluation-27 (ACE-27) 
Checklist 
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Appendix C - Revised Data Key 
Field Valid Data 
Identifier URN (then unique deidentified number) 
Age Integer 
Site Tongue/Floor of Mouth/Oral Cavity Other 
Stage T 1/2/3/4 
Stage N 0/1/2a/2b 
DiagnosisDate Date 
SurgeryDate Date 
Chemo 0: none 
1: induction 
2: concurrent 
3: adjuvant 
XRT 0: none 
1: definitive 
2: adjuvant 
XRTdose integer 
XRTfractionation 0: standard 
1: hyperfractionated 
Recurrence 0/1 
RecurrenceDate Date 
RecurrenceType Local/Node/Distant/Primary 
Death 0/1 
DeathDate Date 
HistoGrade Poorly differentiated 
Moderately differentiated 
Well differentiated 
HistoVascularInvasion 0/1 
HistoPerineuralInvasion 0/1 
HistoMandibularInvasion 0/1 
HistoExtracapsularSpread 0/1 
HistoMargin 0: clear 
1: close (<5mm) 
2: involved 
HistoNodalYield Integer 
SurgeryMandibularResection 0/1 
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SurgeryNeckDissection 0/1 
SurgerySalvage 0/1 
SurgerySalvageDate Date 
Smoking 0: Never 
1: Light (1 - 10 packyears) 
2: Moderate-Heavy (>10 packyears) 
Alcohol 0: Never 
1: Light-Moderate 
2: Heavy 
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Appendix D  - Antibody optimisation schedule
Antibody Buffer Serum Retrieval  1° Antibody Incubation Polymer Chromogen 
hSSB1 (Sheep 
serum purified Ab) 
TBS Horse EDTA 
15'@105 
1:350 Da Vinci 
Green 
1 Hr RT Mach 3 GOAT Probe & 
HRP 
ImmPACT 
DAB 
BANF1 (Sigma 
SAB1409950) 
TBS  Sniper Citrate 
30''@125 
1:350 Da Vinci 
Green 
1 Hr RT Mach1 MsProbe & HRP Betazoid 
DAB 
RNF8 (Sigma 
HPA050731) 
TBS Sniper EDTA 
15'@105 
1:100 Da Vinci 
green 
1 Hr RT Mach 1 Universal HRP Betazoid 
DAB 
OGG1 (Abcam 
ab62826) 
TBS Horse Citrate 
5'@125 
1:50 Da Vinci 
Green 
Onite RT Mach2 Rabbit HRP ImmPACT 
DAB 
PARP1 (Sigma 
HPA045168) 
TBS Sniper EDTA 
15'@105 
1:200 Da Vinci 
green 
1 Hr RT Mach 1 Universal HRP Betazoid 
DAB 
Ku70 
(WH0002547M1 
SIGMA) 
TBS Sniper EDTA 
15'@105 
1:100 Da Vinci 
green 
1 Hr RT Mach 1 Universal HRP Betazoid 
DAB 
ATM (Millipore 
mab3806) 
TBS Sniper EDTA & 
Citrate 
1:100 Da Vinci 
Green 
1 Hr RT Mach 1 Universal HRP Betazoid 
DAB 
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Appendix E - The Base Excision Pathway 
 
 
  
hOGG, 
hNTH 
Base 
lesion  
AP site 
Monofunctional DNA 
glycosolases* 
AP 
Endonuclease 
(APEX1) 
5'-dRP 
blocking 1nt 
gap 
Flap 
endonuclease 
(FEN1) 
3'PUA 
blocking 1nt 
gap 
3'-phosphate 
blocking 1nt 
gap 
3'-OH, 5'-P 1nt 
gap 
NEIL1 & 
2 
Long-patch 
repair 
Short-patch 
repair 
PNK 
ionising 
radiation 
Early steps in base excision repair 
 * monofunctional DNA glycosolases including MPG, UNG, hMYH, hSMUG, TDG and MBD4 
 1nt - one-nucleotide,   dRP - deoxyribophosphate,    3'PUA - 3' phospho α,β-unsaturated 
aldehyde, AP site - apurinic/apyridimic site (or abasic site) 
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Appendix F -  The Nucleotide Excision Pathway 
 
 
 
XPG 
TFIIH 
RPA 
XPA 
XPC-Rad23B 
UV-DDB (for 
CBD and 6-4 
lesions) 
Bulky DNA lesion 
 
 
 
 
 
 
 XPF-
ERCC1 
RPC 
PCNA  
DNA polδ or 
ε DNA ligase  
RPA 
DNA polδ  
XRCC1 
DNA ligase IIIα 
RPA 
 
OR 
PARP 
XPC-Rad23B (also known as XPC-hHR23B) recognizes and binds to bulky lesions, preceded by the 
PARP-mediated UV-DDB heterotrimer in UV-induced lesions [1]. This then recruits XPA, RPA and 
Transcription Factor II H (TFIIH), a complex of 10 subunits including XPD and XPB. The XPD and XPB 
subunits are helicases, which allows the proteins XPG to incise the 3' side of the lesion, and XPF-ERCC1 
to incise the 5' side. The resulting gap of 24-32 bases is ligated by one of two pathways, involving RPC, 
PCNA, DNA polδ or ε, DNA ligase and RPA; or DNA polδ, XRCC1 and DNA ligase IIIα [2]. 
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Appendix G – Supplementary Results Figures  
Figure 5.08-60 - Population characteristics of patients with clear surgical margins 
Figure 5.08-61 - Population characteristics of patients with close or involved surgical margins 
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Figure 5.08-63 - Population characteristics of the no-radiotherapy 
subgroup 
Figure 5.08-62 - Population characteristics of the radiotherapy subgroup 
 
 
107 
 
Bibliography 
 
 
1. Robu, M., et al., Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA 
lesions by nucleotide excision repair. Proceedings of the National Academy of Sciences, 2013. 
110(5): p. 1658-1663. 
2. Shuck, S.C., E.A. Short, and J.J. Turchi, Eukaryotic nucleotide excision repair: from 
understanding mechanisms to influencing biology. Cell Res, 2008. 18(1): p. 64-72. 
3. Ferlay, J., et al., GLOBOCAN Cancer Incidence and Mortality. 2008: http://globocan.iarc.fr. 
4. Giordano, S.H., et al., Is breast cancer survival improving? Cancer, 2004. 100(1): p. 44-52. 
5. Mitry, E., et al., Improvement in colorectal cancer survival: A population-based study. 
European Journal of Cancer, 2005. 41(15): p. 2297-2303. 
6. Horner, M., et al., SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. 
Bethesda, MD. 2009. 
7. Rogers, S.N., et al., Survival following primary surgery for oral cancer. Oral Oncology, 2009. 
45(3): p. 201-211. 
8. Neville, B.W. and T.A. Day, Oral Cancer and Precancerous Lesions. CA: A Cancer Journal for 
Clinicians, 2002. 52(4): p. 195-215. 
9. Jemal, A., et al., Global cancer statistics. CA: A Cancer Journal for Clinicians, 2011. 61(2): p. 
69-90. 
10. Warnakulasuriya, S., Global epidemiology of oral and oropharyngeal cancer. Oral oncology, 
2009. 45(4): p. 309-316. 
11. Goldenberg, D., et al., Habitual risk factors for head and neck cancer. Otolaryngology-Head 
and Neck Surgery, 2004. 131(6): p. 986-993. 
12. Chaturvedi, A.K., et al., Worldwide trends in incidence rates for oral cavity and 
oropharyngeal cancers. Journal of Clinical Oncology, 2013: p. JCO-2013. 
13. Gupta, B., A. Ariyawardana, and N.W. Johnson, Oral cancer in India continues in epidemic 
proportions: evidence base and policy initiatives. International dental journal, 2013. 63(1): p. 
12-25. 
14. Hashibe, M., et al., Alcohol Drinking in Never Users of Tobacco, Cigarette Smoking in Never 
Drinkers, and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head 
and Neck Cancer Epidemiology Consortium. Journal of the National Cancer Institute, 2007. 
99(10): p. 777-789. 
15. Hashibe, M., et al., Interaction between Tobacco and Alcohol Use and the Risk of Head and 
Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology 
Consortium. Cancer Epidemiology Biomarkers & Prevention, 2009. 18(2): p. 541-550. 
16. Rothman, K. and A. Keller, The effect of joint exposure to alcohol and tobacco on risk of 
cancer of the mouth and pharynx. Journal of chronic diseases, 1972. 25(12): p. 711-716. 
17. Gillison, M.L., et al., Tobacco smoking and increased risk of death and progression for 
patients with p16-positive and p16-negative oropharyngeal cancer. Journal of Clinical 
Oncology, 2012. 30(17): p. 2102-2111. 
18. Warnakulasuriya, S., N.W. Johnson, and I. Van Der Waal, Nomenclature and classification of 
potentially malignant disorders of the oral mucosa. Journal of Oral Pathology & Medicine, 
2007. 36(10): p. 575-580. 
19. Tanić, N., et al., Genomic instability and tumor-specific DNA alterations in oral leukoplakias. 
European Journal of Oral Sciences, 2009. 117(3): p. 231-237. 
20. Waldron, C.A. and W.G. Shafer, Leukoplakia revisited. A clinicopathologic study 3256 oral 
leukoplakias. Cancer, 1975. 36(4): p. 1386-1392. 
 
 
108 
 
21. Lind, P.O., Malignant transformation in oral leukoplakia. European Journal of Oral Sciences, 
1987. 95(6): p. 449-455. 
22. Schepman, K.P., et al., Malignant transformation of oral leukoplakia: a follow-up study of a 
hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral 
Oncology, 1998. 34(4): p. 270-275. 
23. Silverman, S., et al., Malignant transformation and natural history of oral leukoplakia in 
57,518 industrial workers of gujarat, india. Cancer, 1976. 38(4): p. 1790-1795. 
24. Sturgis, E.M. and P.M. Cinciripini, Trends in head and neck cancer incidence in relation to 
smoking prevalence. Cancer, 2007. 110(7): p. 1429-1435. 
25. Scheffner, M., et al., The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein 
ligase in the ubiquitination of p53. Cell, 1993. 75(3): p. 495-505. 
26. Thomas, M., D. Pim, and L. Banks, The role of the E6-p53 interaction in the molecular 
pathogenesis of HPV. Oncogene, 1999. 18(53): p. 7690. 
27. Mietz, J.A., et al., The transcriptional transactivation function of wild-type p53 is inhibited by 
SV40 large T-antigen and by HPV-16 E6 oncoprotein. The EMBO journal, 1992. 11(13): p. 
5013. 
28. Dayyani, F., et al., Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk 
and overall survival in head and neck squamous cell carcinomas (HNSCC). Head & Neck 
Oncology, 2010. 2(1): p. 15. 
29. Ang, K.K., et al., Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. 
The New England Journal of Medicine, 2010. 363(1): p. 24-35. 
30. Termine, N., et al., HPV in oral squamous cell carcinoma vs head and neck squamous cell 
carcinoma biopsies: a meta-analysis (1988–2007). Annals of Oncology, 2008. 19(10): p. 
1681-1690. 
31. Kansy, K., O. Thiele, and K. Freier, The role of human papillomavirus in oral squamous cell 
carcinoma: myth and reality. Oral and Maxillofacial Surgery, 2012: p. 1-8. 
32. Yakushiji, T., et al., Over-expression of DNA methyltransferases and CDKN2A gene 
methylation status in squamous cell carcinoma of the oral cavity. International journal of 
oncology, 2003. 22(6): p. 1201. 
33. Reed, A.L., et al., High Frequency of p16 (CDKN2/MTS-1/INK4A) Inactivation in Head and 
Neck Squamous Cell Carcinoma. Cancer Research, 1996. 56(16): p. 3630-3633. 
34. Tsai, C.-H., et al., The correlation between alteration of p16 gene and clinical status in oral 
squamous cell carcinoma. Journal of Oral Pathology & Medicine, 2001. 30(9): p. 527-531. 
35. Duray, A., et al., Human papillomavirus DNA strongly correlates with a poorer prognosis in 
oral cavity carcinoma. The Laryngoscope, 2012. 122(7): p. 1558-1565. 
36. Llewellyn, C.D., N.W. Johnson, and K.A.A.S. Warnakulasuriya, Risk factors for squamous cell 
carcinoma of the oral cavity in young people — a comprehensive literature review. Oral 
Oncology, 2001. 37(5): p. 401-418. 
37. Schantz Sp, Y.G., Head and neck cancer incidence trends in young americans, 1973-1997, 
with a special analysis for tongue cancer. Archives of Otolaryngology–Head & Neck Surgery, 
2002. 128(3): p. 268-274. 
38. Friedlander, P.L., et al., Squamous cell carcinoma of the tongue in young patients: A 
matched-pair analysis. Head & Neck, 1998. 20(5): p. 363-368. 
39. Garavello, W., R. Spreafico, and R.M. Gaini, Oral tongue cancer in young patients: A matched 
analysis. Oral Oncology, 2007. 43(9): p. 894-897. 
40. Pfeiffer, J., et al., Head and neck cancer in young adults and nonsmokers: Study of cancer 
susceptibility by genome-wide high-density SNP microarray mapping. Acta Oto-laryngologica, 
2011. 131(10): p. 1091-1098. 
41. Haddadin, K.J., et al., Natural history and patterns of recurrence of tongue tumours. British 
Journal of Plastic Surgery, 2000. 53(4): p. 279-285. 
 
 
109 
 
42. Woolgar, J.A., Pathology of the N0 neck. British Journal of Oral and Maxillofacial Surgery, 
1999. 37(3): p. 205-209. 
43. Ho, C.M., et al., Occult lymph node metastasis in small oral tongue cancers. Head & Neck, 
1992. 14(5): p. 359-363. 
44. Teichgraeber, J.F. and A.A. Clairmont, The incidence of occult metastases for cancer of the 
oral tongue and floor of the mouth: Treatment rationale. Head & Neck Surgery, 1984. 7(1): p. 
15-21. 
45. El-Naaj, I.A., et al., Incidence of oral cancer occult metastasis and survival of T1-T2N0 oral 
cancer patients. Journal of Oral and Maxillofacial Surgery, 2011. 69(10): p. 2674-2679. 
46. Spiro, R.H., et al., Pattern of invasion and margin assessment in patients with oral tongue 
cancer. Head & Neck, 1999. 21(5): p. 408-413. 
47. Veness, M.J., et al., Anterior tongue cancer and the incidence of cervical lymph node 
metastases with increasing tumour thickness: should elective treatment to the neck be 
standard practice in all patients? ANZ Journal of Surgery, 2005. 75(3): p. 101-105. 
48. Sparano, A., et al., Multivariate Predictors of Occult Neck Metastasis in Early Oral Tongue 
Cancer. Otolaryngology -- Head and Neck Surgery, 2004. 131(4): p. 472-476. 
49. Asakage, T., et al., Tumor thickness predicts cervical metastasis in patients with stage I/II 
carcinoma of the tongue. Cancer, 1998. 82(8): p. 1443-1448. 
50. Sano, D. and J.N. Myers, Metastasis of squamous cell carcinoma of the oral tongue. Cancer 
and Metastasis Reviews, 2007. 26(3-4): p. 645-62. 
51. Lindberg, R., Distribution of cervical lymph node metastases from squamous cell carcinoma 
of the upper respiratory and digestive tracts. Cancer, 1972. 29(6): p. 1446-1449. 
52. Arduino, P.G., et al., Clinical and histopathologic independent prognostic factors in oral 
squamous cell carcinoma: a retrospective study of 334 cases. Journal of Oral and 
Maxillofacial Surgery, 2008. 66(8): p. 1570-1579. 
53. Ebrahimi, A., B.G. Ashford, and J.R. Clark, Improved survival with elective neck dissection in 
thick early-stage oral squamous cell carcinoma. Head & Neck, 2012. 34(5): p. 709-716. 
54. Fasunla, A.J., et al., A meta-analysis of the randomized controlled trials on elective neck 
dissection versus therapeutic neck dissection in oral cavity cancers with clinically node-
negative neck. Oral Oncology, 2011. 47(5): p. 320-324. 
55. Bessell, A., et al., Interventions for the treatment of oral and oropharyngeal cancers: surgical 
treatment. Cochrane Database of Systematic Reviews, 2011(4). 
56. Williams, R.G., Recurrent head and neck cancer: The results of treatment. British Journal of 
Surgery, 1974. 61(9): p. 691-697. 
57. Wong, L.Y., et al., Salvage of recurrent head and neck squamous cell carcinoma after primary 
curative surgery. Head & Neck, 2003. 25(11): p. 953-959. 
58. Brown, J.S., et al., Systematic review of the current evidence in the use of postoperative 
radiotherapy for oral squamous cell carcinoma. British Journal of Oral and Maxillofacial 
Surgery, 2012. 50(6): p. 481-489. 
59. Gomez, D.R., et al., Intensity-Modulated Radiotherapy in Postoperative Treatment of Oral 
Cavity Cancers. International Journal of Radiation Oncology*Biology*Physics, 2009. 73(4): p. 
1096-1103. 
60. Parsons, J.T., et al., Hyperfractionation for head and neck cancer. International Journal of 
Radiation Oncology*Biology*Physics, 1988. 14(4): p. 649-658. 
61. Glenny, A., et al., The CSROC Expert Panel. Interventions for the treatment of oral cavity and 
oropharyngeal cancer: radiotherapy. Cochrane Database of Systematic Reviews, 2010(12). 
62. Bourhis, J., et al., Hyperfractionated or accelerated radiotherapy in head and neck cancer: a 
meta-analysis. Lancet, 2006. 368(9538): p. 843-854. 
63. Eisbruch, A., et al., Xerostomia and its predictors following parotid-sparing irradiation of 
head-and-neck cancer. International Journal of Radiation Oncology*Biology*Physics, 2001. 
50(3): p. 695-704. 
 
 
110 
 
64. Cooper, J.S., et al., Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk 
Squamous-Cell Carcinoma of the Head and Neck. The New England Journal of Medicine, 
2004. 350(19): p. 1937-44. 
65. National Comprehensive Cancer Network. Head and Neck Cancers   [cited 2013 3/4/13]; 
1.2012:[Available from: http://www.nccn.org/professionals/physician_gls/pdf/head-and-
neck.pdf. 
66. Merlano, M., et al., Treatment of Advanced Squamous-Cell Carcinoma of the Head and Neck 
with Alternating Chemotherapy and Radiotherapy. The New England Journal of Medicine, 
1992. 327(16): p. 1115-1121. 
67. Pignon, J.-P., et al., Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An 
update on 93 randomised trials and 17,346 patients. Radiotherapy and Oncology, 2009. 
92(1): p. 4-14. 
68. Furness, S., et al., Interventions for the treatment of oral cavity and oropharyngeal cancer: 
chemotherapy. Cochrane Database of Systematic Reviews, 2011. 4. 
69. Pignon, J.P., et al., Chemotherapy added to locoregional treatment for head and neck 
squamous-cell carcinoma: Three meta-analyses of updated individual data. The Lancet, 
2000. 355(9208): p. 949-55. 
70. Logan, R.M., Advances in understanding of toxicities of treatment for head and neck cancer. 
Oral Oncology, 2009. 45(10): p. 844-848. 
71. Posner, M.R., et al., Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck 
Cancer. New England Journal of Medicine, 2007. 357(17): p. 1705-1715. 
72. Bonner, J.A., et al., Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head 
and Neck. The New England Journal of Medicine, 2006. 354(6): p. 567-78. 
73. Bonner, J.A., et al., Radiotherapy plus cetuximab for locoregionally advanced head and neck 
cancer: 5-year survival data from a phase 3 randomised trial, and relation between 
cetuximab-induced rash and survival. The Lancet Oncology, 2010. 11(1): p. 21-28. 
74. Ali, M.A.L.S., et al., Expression and mutation analysis of epidermal growth factor receptor in 
head and neck squamous cell carcinoma. Cancer Science, 2008. 99(8): p. 1589-1594. 
75. Huang, S.-F., et al., EGFR protein overexpression and mutation in areca quid–associated oral 
cavity squamous cell carcinoma in Taiwan. Head & Neck, 2009. 31(8): p. 1068-1077. 
76. Bentzen, S.M., et al., Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies 
From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From 
Accelerated Radiation Therapy in a Randomized Controlled Trial. Journal of Clinical Oncology, 
2005. 23(24): p. 5560-5567. 
77. Piccirillo, J.F., Importance of Comorbidity in Head and Neck Cancer. The Laryngoscope, 2000. 
110(4): p. 593-602. 
78. Michiels, S., et al., Surrogate endpoints for overall survival in locally advanced head and neck 
cancer: meta-analyses of individual patient data. Lancet Oncology, 2009. 10(4): p. 341-50. 
79. Chen, T.-C., et al., The Impact of Perineural Invasion and/or Lymphovascular Invasion on the 
Survival of Early-Stage Oral Squamous Cell Carcinoma Patients. Annals of Surgical Oncology, 
2013. Prepublication: p. 1-8. 
80. Piccirillo Jf, T.R.M.C.I.G.L.S.J.E.L., Prognostic importance of comorbidity in a hospital-based 
cancer registry. JAMA, 2004. 291(20): p. 2441-2447. 
81. Bang, D., et al. The Adult Comorbidity Evaluation-27 (ACE-27) test: a new comorbidity index 
for patients with cancer. in Annual Meeting of the American Society of Clinical Oncology. 
2000. 
82. Paleri, V. and R.G. Wight, A cross-comparison of retrospective notes extraction and combined 
notes extraction and patient interview in the completion of a comorbidity index (ACE-27) in a 
cohort of United Kingdom patients with head and neck cancer. The Journal of Laryngology & 
Otology, 2002. 116(11): p. 937-941. 
 
 
111 
 
83. Jones, K.R., et al., Prognostic factors in the recurrence of stage I and II squamous cell cancer 
of the oral cavity. Archives of Otolaryngology—Head & Neck Surgery, 1992. 118(5): p. 483. 
84. van der Schroeff, M.P., et al., Prognosis: A variable parameter. Dynamic prognostic modeling 
in head and neck squamous cell carcinoma. Head & neck, 2012. 34(1): p. 34-41. 
85. Baatenburg de Jong, R.J., et al., Prediction of survival in patients with head and neck cancer. 
Head & neck, 2001. 23(9): p. 718-724. 
86. Atkinson, A.J., et al., Biomarkers and surrogate endpoints: Preferred definitions and 
conceptual framework. Clinical Pharmacology & Therapeutics, 2001. 69(3): p. 89-95. 
87. Engstrom, P.F., et al., NCCN molecular testing white paper: effectiveness, efficiency, and 
reimbursement. Journal of the National Comprehensive Cancer Network, 2011. 9(Suppl 6): p. 
S-1-S-16. 
88. Haber, Daniel A., Nathanael S. Gray, and J. Baselga, The Evolving War on Cancer. Cell, 2011. 
145(1): p. 19-24. 
89. Xie, X., et al., Prognostic significance of proliferative and apoptotic markers in oral tongue 
squamous cell carcinomas. Oral Oncology, 1999. 35(5): p. 502-509. 
90. Freier, K., et al., High survivin expression is associated with favorable outcome in advanced 
primary oral squamous cell carcinoma after radiation therapy. International Journal of 
Cancer, 2007. 120(4): p. 942-946. 
91. Kim, Y.H., et al., Evaluation of survivin as a prognostic marker in oral squamous cell 
carcinoma. Journal of oral pathology & medicine, 2009. 39(5): p. 368-375. 
92. Ang, K.K., et al., Impact of Epidermal Growth Factor Receptor Expression on Survival and 
Pattern of Relapse in Patients with Advanced Head and Neck Carcinoma. Cancer Research, 
2002. 62(24): p. 7350-7356. 
93. Chung, C.H., et al., Increased epidermal growth factor receptor gene copy number is 
associated with poor prognosis in head and neck squamous cell carcinomas. Journal of 
Clinical Oncology, 2006. 24(25): p. 4170-4176. 
94. Grandis, J.R., et al., Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell 
Carcinoma and Patient Survival. Journal of the National Cancer Institute, 1998. 90(11): p. 
824-832. 
95. Carlos de Vicente, J., et al., Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of 
the oral cavity: clinicopathological and prognostic significance. Oral Oncology, 2002. 38(3): p. 
301-308. 
96. Hassan, K.A., et al., Clinical Significance of Cyclin B1 Protein Expression in Squamous Cell 
Carcinoma of the Tongue. Clinical Cancer Research, 2001. 7(8): p. 2458-2462. 
97. Kyzas, P.A., I.W. Cunha, and J.P.A. Ioannidis, Prognostic Significance of Vascular Endothelial 
Growth Factor Immunohistochemical Expression in Head and Neck Squamous Cell 
Carcinoma: A Meta-Analysis. Clinical Cancer Research, 2005. 11(4): p. 1434-1440. 
98. Zhang, B., et al., The expression and significance of MRP1, LRP, TOPOIIβ, and BCL2 in tongue 
squamous cell carcinoma. Journal of Oral Pathology & Medicine, 2012. 41(2): p. 141-148. 
99. Roh, J.-L., et al., The prognostic value of hypoxia markers in T2-staged oral tongue cancer. 
Oral Oncology, 2009. 45(1): p. 63-68. 
100. Bristow, R.G. and R.P. Hill, Hypoxia and metabolism: hypoxia, DNA repair and genetic 
instability. Nature Reviews Cancer, 2008. 8(3): p. 180-192. 
101. Chan, N., et al., Chronic hypoxia decreases synthesis of homologous recombination proteins 
to offset chemoresistance and radioresistance. Cancer research, 2008. 68(2): p. 605-614. 
102. Jun, H., et al., ERCC1 expression as a predictive marker of squamous cell carcinoma of the 
head and neck treated with cisplatin-based concurrent chemoradiation. British journal of 
cancer, 2008. 99(1): p. 167-172. 
103. Moeller, B.J., et al., DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 
Expression Predicts Locoregional Failure and Death following Radiotherapy. Clinical Cancer 
Research, 2011. 17(7): p. 2035-2043. 
 
 
112 
 
104. Olaussen, K.A., et al., DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-
Based Adjuvant Chemotherapy. New England Journal of Medicine, 2006. 355(10): p. 983-
991. 
105. Pavón, M.A., et al., Ku70 predicts response and primary tumor recurrence after therapy in 
locally advanced head and neck cancer. International Journal of Cancer, 2008. 123(5): p. 
1068-1079. 
106. Peng, B., et al., Microarray-Assisted Pathway Analysis Identifies MT1X & NFκB as Mediators 
of TCRP1-Associated Resistance to Cisplatin in Oral Squamous Cell Carcinoma. PloS one, 
2012. 7(12): p. e51413. 
107. Peng, B., et al., Purification and biochemical characterization of a novel protein—tongue 
cancer chemotherapy resistance-associated protein1 (TCRP1). Protein Expression and 
Purification, 2012. 82: p. 360-367. 
108. Vaezi, A., et al., XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma 
of the Head and Neck. Clinical Cancer Research, 2011. 17(16): p. 5513-5522. 
109. Wang, Y.F., et al., Prognostic significance of nm23-H1 expression in oral squamous cell 
carcinoma. Br J Cancer, 2004. 90(11): p. 2186-2193. 
110. Zhai, X., et al., Functional variants of the NEIL1 and NEIL2 genes and risk and progression of 
squamous cell carcinoma of the oral cavity and oropharynx. Clinical Cancer Research, 2008. 
14(13): p. 4345-4352. 
111. Tremblay S, P.d.R.P.B.G. and et al., Young patients with oral squamous cell carcinoma: Study 
of the involvement of gstp1 and deregulation of the fanconi anemia genes. Archives of 
Otolaryngology–Head & Neck Surgery, 2006. 132(9): p. 958-966. 
112. Wilson, M.A. and K.L. Nathanson, Molecular Testing in Melanoma. The Cancer Journal, 2012. 
18(2): p. 117-123 10.1097/PPO.0b013e31824f11bf. 
113. Teutsch, S.M., et al., The Evaluation of Genomic Applications in Practice and Prevention 
(EGAPP) initiative: methods of the EGAPP working group. Genetics in Medicine, 2009. 11(1): 
p. 3-14. 
114. Lindahl, T. and D. Barnes. Repair of endogenous DNA damage. in Cold Spring Harbor 
symposia on quantitative biology. 2000. Cold Spring Harbor Laboratory Press. 
115. Vilenchik, M.M. and A.G. Knudson, Endogenous DNA double-strand breaks: Production, 
fidelity of repair, and induction of cancer. Proceedings of the National Academy of Sciences, 
2003. 100(22): p. 12871-12876. 
116. Rich, T., R.L. Allen, and A.H. Wyllie, Defying death after DNA damage. Nature, 2000. 
407(6805): p. 777-83. 
117. Hakem, R., DNA-damage repair; the good, the bad, and the ugly. EMBO Journal, 2008. 27(4): 
p. 589-605. 
118. Gorgoulis, V.G., et al., Activation of the DNA damage checkpoint and genomic instability in 
human precancerous lesions. Nature, 2005. 434(7035): p. 907-913. 
119. DiTullio, R.A., et al., 53BP1 functions in an ATM-dependent checkpoint pathway that is 
constitutively activated in human cancer. Nature Cell Biology, 2002. 4(12): p. 998-1002. 
120. Bartek, J., J. Bartkova, and J. Lukas, DNA damage signalling guards against activated 
oncogenes and tumour progression. Oncogene, 2007. 26(56): p. 7773-9. 
121. Sancar, A., et al., Molecular mechanisms of mammalian DNA repair and the DNA damage 
checkpoints. Annual Review of Biochemistry, 2004. 73(1): p. 39-85. 
122. Bau, D.-T., et al., Association between DNA repair gene ATM polymorphisms and oral cancer 
susceptibility. The Laryngoscope, 2010. 120(12): p. 2417-2422. 
123. Ai, L., et al., Ataxia-Telangiectasia-Mutated (ATM) Gene in Head and Neck Squamous Cell 
Carcinoma: Promoter Hypermethylation with Clinical Correlation in 100 Cases. Cancer 
Epidemiology Biomarkers & Prevention, 2004. 13(1): p. 150-156. 
 
 
113 
 
124. Rigi-Ladiz, M.A., D.M. Kordi-Tamandani, and A. Torkamanzehi, Analysis of hypermethylation 
and expression profiles of APC and ATM genes in patients with oral squamous cell carcinoma. 
Clinical epigenetics, 2011. 3(1): p. 1-6. 
125. Fernandez-Capetillo, O., et al., H2AX: the histone guardian of the genome. DNA Repair, 2004. 
3(8–9): p. 959-967. 
126. Kinner, A., et al., γ-H2AX in recognition and signaling of DNA double-strand breaks in the 
context of chromatin. Nucleic Acids Research, 2008. 36(17): p. 5678-5694. 
127. Fernandez-Capetillo, O., et al., DNA damage-induced G2-M checkpoint activation by histone 
H2AX and 53BP1. Nature Cell Biology, 2002. 4(12): p. 993-7. 
128. Schultz, L.B., et al., P53 Binding Protein 1 (53bp1) Is an Early Participant in the Cellular 
Response to DNA Double-Strand Breaks. The Journal of Cell Biology, 2000. 151(7): p. 1381-
1390. 
129. Yentram, H., et al., Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand 
breaks. Nature, 2004. 432(7015): p. 406-11. 
130. Chiu, T.J., et al., High ERCC1 expression predicts cisplatin-based chemotherapy resistance and 
poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing 
area. J Transl Med, 2011. 9: p. 31. 
131. Sanders, S.L., et al., Methylation of Histone H4 Lysine 20 Controls Recruitment of Crb2 to 
Sites of DNA Damage. Cell, 2004. 119(5): p. 603-614. 
132. Botuyan, M.V., et al., Structural Basis for the Methylation State-Specific Recognition of 
Histone H4-K20 by 53BP1 and Crb2 in DNA Repair. Cell, 2006. 127(7): p. 1361-1373. 
133. Mok, M.T.S. and B.R. Henderson, The in vivo dynamic interplay of MDC1 and 53BP1 at DNA 
damage-induced nuclear foci. The International Journal of Biochemistry & Cell Biology, 2012. 
44(9): p. 1398-1409. 
134. Rappold, I., et al., Tumor Suppressor P53 Binding Protein 1 (53bp1) Is Involved in DNA 
Damage–Signaling Pathways. The Journal of Cell Biology, 2001. 153(3): p. 613-620. 
135. Wang, B., et al., 53BP1, a Mediator of the DNA Damage Checkpoint. Science, 2002. 
298(5597): p. 1435-1438. 
136. Mailand, N., et al., RNF8 Ubiquitylates Histones at DNA Double-Strand Breaks and Promotes 
Assembly of Repair Proteins. Cell, 2007. 131(5): p. 887-900. 
137. Sakasai, R. and R. Tibbetts, RNF8-dependent and RNF8-independent Regulation of 53BP1 in 
Response to DNA Damage. Journal of Biological Chemistry, 2008. 283(20): p. 13549-13555. 
138. Poulsen, M., et al., Human RNF169 is a negative regulator of the ubiquitin-dependent 
response to DNA double-strand breaks. J Cell Biol, 2012. 197(2): p. 189-99. 
139. Coleman, K.A. and R.A. Greenberg, The BRCA1-RAP80 Complex Regulates DNA Repair 
Mechanism Utilization by Restricting End Resection. Journal of Biological Chemistry, 2011. 
286(15): p. 13669-13680. 
140. Escribano-Díaz, C., et al., A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 
and BRCA1-CtIP Controls DNA Repair Pathway Choice. Molecular Cell, 2013. 49(5): p. 872-
883. 
141. Bunting, S.F., et al., 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by 
Blocking Resection of DNA Breaks. Cell, 2010. 141(2): p. 243-254. 
142. Bouwman, P., et al., 53BP1 loss rescues BRCA1 deficiency and is associated with triple-
negative and BRCA-mutated breast cancers. Nature Structural & Molecular Biology, 2010. 
17(6): p. 688-95. 
143. Nakada, S., R.M. Yonamine, and K. Matsuo, RNF8 Regulates Assembly of RAD51 at DNA 
Double-Strand Breaks in the Absence of BRCA1 and 53BP1. Cancer Research, 2012. 72(19): p. 
4974-4983. 
144. Takata, M., et al., Homologous recombination and non-homologous end-joining pathways of 
DNA double-strand break repair have overlapping roles in the maintenance of chromosomal 
integrity in vertebrate cells. EMBO J, 1998. 17(18): p. 5497-5508. 
 
 
114 
 
145. Sonoda, E., et al., Differential usage of non-homologous end-joining and homologous 
recombination in double strand break repair. DNA Repair, 2006. 5(9–10): p. 1021-1029. 
146. Burma, S., B.P.C. Chen, and D.J. Chen, Role of non-homologous end joining (NHEJ) in 
maintaining genomic integrity. DNA Repair, 2006. 5(9–10): p. 1042-1048. 
147. Chappell, C., et al., Involvement of human polynucleotide kinase in double-strand break 
repair by non-homologous end joining. EMBO Journal, 2002. 21(11): p. 2827-32. 
148. Quennet, V., et al., CtIP and MRN promote non-homologous end-joining of etoposide-
induced DNA double-strand breaks in G1. Nucleic Acids Research, 2011. 39(6): p. 2144-2152. 
149. Iliakis, G., et al., Mechanisms of DNA double strand break repair and chromosome aberration 
formation. Cytogenetic and Genome Research, 2004. 104(1-4): p. 14-20. 
150. Fattah, F., et al., Ku regulates the non-homologous end joining pathway choice of DNA 
double-strand break repair in human somatic cells. Plos Genetics, 2010. 6(2): p. e1000855-
e1000855. 
151. Wang, H., et al., DNA Ligase III as a Candidate Component of Backup Pathways of 
Nonhomologous End Joining. Cancer Research, 2005. 65(10): p. 4020-4030. 
152. Wang, M., et al., PARP-1 and Ku compete for repair of DNA double strand breaks by distinct 
NHEJ pathways. Nucleic Acids Research, 2006. 34(21): p. 6170-6182. 
153. Mansour, W.Y., T. Rhein, and J. Dahm-Daphi, The alternative end-joining pathway for repair 
of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. 
Nucleic Acids Research, 2010. 38(18): p. 6065-6077. 
154. Audebert, M., B. Salles, and P. Calsou, Effect of double-strand break DNA sequence on the 
PARP-1 NHEJ pathway. Biochemical and Biophysical Research Communications, 2008. 
369(3): p. 982-988. 
155. Roberts, S.A., et al., Ku is a 5'-dRP/AP lyase that excises nucleotide damage near broken 
ends. Nature, 2010. 464(7292): p. 1214-1217. 
156. Indiviglio, S.M. and A.A. Bertuch, Ku's essential role in keeping telomeres intact. Proceedings 
of the National Academy of Sciences, 2009. 106(30): p. 12217-12218. 
157. Friesland, S., et al., Expression of Ku86 confers favorable outcome of tonsillar carcinoma 
treated with radiotherapy. Head & Neck, 2003. 25(4): p. 313-321. 
158. Sousa, F.G., et al., PARPs and the DNA damage response. Carcinogenesis, 2012. 33(8): p. 
1433-1440. 
159. Sugimura, K., et al., PARP-1 ensures regulation of replication fork progression by homologous 
recombination on damaged DNA. The Journal of Cell Biology, 2008. 183(7): p. 1203-1212. 
160. Schultz, N., et al., Poly(ADPribose) polymerase (PARP1) has a controlling role in homologous 
recombination. Nucleic Acids Research, 2003. 31(17): p. 4959-4964. 
161. De Vos, M., V. Schreiber, and F. Dantzer, The diverse roles and clinical relevance of PARPs in 
DNA damage repair: Current state of the art. Biochemical Pharmacology, 2012. 84(2): p. 137-
146. 
162. Metzger, M.J., B.L. Stoddard, and R.J. Monnat Jr, PARP-mediated repair, homologous 
recombination, and back-up non-homologous end joining-like repair of single-strand nicks. 
DNA Repair, 2013. 12(7): p. 529-534. 
163. Bryant, H.E., et al., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-
ribose) polymerase. Nature, 2005. 434(7035): p. 913-917. 
164. Fong, P.C., et al., Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation 
Carriers. The New England Journal of Medicine, 2009. 361(2): p. 123-34. 
165. Nowsheen, S., et al., Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase 
inhibition in head and neck cancer. Plos One, 2011. 6(8): p. e24148-e24148. 
166. Ibrahim, Y.H., et al., PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-
Proficient Triple-Negative Breast Cancer to PARP Inhibition. Cancer Discovery, 2012. 2(11): p. 
1036-1047. 
 
 
115 
 
167. McCabe, N., et al., Deficiency in the Repair of DNA Damage by Homologous Recombination 
and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition. Cancer Research, 2006. 66(16): p. 
8109-8115. 
168. Yamashita, T., et al., The Role of PARP 1 for Cisplatin-Based Chemoresistance. Otolaryngology 
-- Head and Neck Surgery, 2010. 143(2 suppl): p. P54. 
169. Symington, L.S. and J. Gautier, Double-Strand Break End Resection and Repair Pathway 
Choice. Annual Review of Genetics, 2011. 45(1): p. 247-271. 
170. Heyer, W.-D., K.T. Ehmsen, and J. Liu, Regulation of homologous recombination in 
eukaryotes. Annual review of genetics, 2010. 44: p. 113-139. 
171. Ciccia, A. and S.J. Elledge, The DNA Damage Response: Making It Safe to Play with Knives. 
Molecular Cell, 2010. 40(2): p. 179-204. 
172. Richard, D.J., et al., hSSB1 interacts directly with the MRN complex stimulating its 
recruitment to DNA double-strand breaks and its endo-nuclease activity. Nucleic Acids 
Research, 2011. 39(9): p. 3643-3651. 
173. Wang, Y., et al., Mutation in Rpa1 results in defective DNA double-strand break repair, 
chromosomal instability and cancer in mice. Nature genetics, 2005. 37(7): p. 750-755. 
174. Zou, L. and S.J. Elledge, Sensing DNA damage through ATRIP recognition of RPA-ssDNA 
complexes. Science Signalling, 2003. 300(5625): p. 1542. 
175. Liu, J., et al., Human BRCA2 protein promotes RAD51 filament formation on RPA-covered 
single-stranded DNA. Nature structural & molecular biology, 2010. 17(10): p. 1260-1262. 
176. Sy, S.M.H., M.S.Y. Huen, and J. Chen, PALB2 is an integral component of the BRCA complex 
required for homologous recombination repair. Proceedings of the National Academy of 
Sciences, 2009. 106(17): p. 7155-7160. 
177. Richard, D.J., et al., Single-stranded DNA-binding protein hSSB1 is critical for genomic 
stability. Nature, 2008. 453(7195): p. 677-681. 
178. Richard, D.J., et al., hSSB1 rapidly binds at the sites of DNA double-strand breaks and is 
required for the efficient recruitment of the MRN complex. Nucleic acids research, 2011. 
39(5): p. 1692-1702. 
179. Skaar, J.R., et al., INTS3 controls the hSSB1-mediated DNA damage response. The Journal of 
cell biology, 2009. 187(1): p. 25-32. 
180. Huang, J., et al., SOSS complexes participate in the maintenance of genomic stability. 
Molecular cell, 2009. 35(3): p. 384-393. 
181. Xu, S., et al., hSSB1 binds and protects p21 from ubiquitin-mediated degradation and 
positively correlates with p21 in human hepatocellular carcinomas. Oncogene, 2011. 30(19): 
p. 2219-29. 
182. Thompson, D., D.F. Easton, and t.B.C.L. Consortium, Cancer Incidence in BRCA1 Mutation 
Carriers. Journal of the National Cancer Institute, 2002. 94(18): p. 1358-1365. 
183. Ford, D., et al., Risks of cancer in BRCA1-mutation carriers. The Lancet, 1994. 343(8899): p. 
692-695. 
184. Hu, Y., et al., RAP80-directed tuning of BRCA1 homologous recombination function at 
ionizing radiation-induced nuclear foci. Genes & Development, 2011. 25(7): p. 685-700. 
185. Vora, H.H., et al., BRCA1 expression in leukoplakia and carcinoma of the tongue. Journal of 
Surgical Oncology, 2003. 83(4): p. 232-240. 
186. Taron, M., et al., BRCA1 mRNA expression levels as an indicator of chemoresistance in lung 
cancer. Human Molecular Genetics, 2004. 13(20): p. 2443-2449. 
187. Tobin, L.A., et al., Targeting Abnormal DNA Repair in Therapy-Resistant Breast Cancers. 
Molecular Cancer Research, 2012. 10(1): p. 96-107. 
188. Nawroz-Danish, H.M., et al., Lack of BRCA2 alterations in primary head and neck squamous 
cell carcinoma. Otolaryngology -- Head and Neck Surgery, 1998. 119(1): p. 21-25. 
189. Marsit, C.J., et al., Inactivation of the Fanconi anemia/BRCA pathway in lung and oral 
cancers: implications for treatment and survival. Oncogene, 2004. 23(4): p. 1000-4. 
 
 
116 
 
190. Wang, L.E., et al., Mutagen sensitivity to benzo(a)pyrene diol epoxide and the risk of 
squamous cell carcinoma of the head and neck. Clinical Cancer Research, 1998. 4(7): p. 1773-
1778. 
191. Cleaver, J.E., Photosensitivity syndrome brings to light a new transcription-coupled DNA 
repair cofactor. Nat Genet, 2012. 44(5): p. 477-478. 
192. Wei, L., et al., BRCA1 contributes to transcription-coupled repair of DNA damage through 
polyubiquitination and degradation of Cockayne syndrome B protein. Cancer Science, 2011. 
102(10): p. 1840-1847. 
193. Kamenisch, Y. and M. Berneburg, Progeroid syndromes and UV-induced oxidative DNA 
damage. The Journal Of Investigative Dermatology. Symposium Proceedings / The Society 
For Investigative Dermatology, Inc. [And] European Society For Dermatological Research, 
2009. 14(1): p. 8-14. 
194. Wijnhoven, S.W.P., et al., The Relationship between Benzo[a]pyrene-induced Mutagenesis 
and Carcinogenesis in Repair-deficient Cockayne Syndrome Group B Mice. Cancer Research, 
2000. 60(20): p. 5681-5687. 
195. Handra-Luca, A., et al., Excision Repair Cross Complementation Group 1 
Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in 
Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and 
Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2007. 13(13): p. 3855-3859. 
196. Tsai, L.-L., et al., Enhanced cisplatin resistance in oral-cancer stem-like cells is correlated with 
upregulation of excision-repair cross-complementation group 1. Journal of Dental Sciences, 
2012. 7(2): p. 111-117. 
197. Ahmad, A., et al., ERCC1-XPF Endonuclease Facilitates DNA Double-Strand Break Repair. 
Molecular and Cellular Biology, 2008. 28(16): p. 5082-5092. 
198. Wang, Y., et al., Nucleotide Excision Repair Pathway Genes and Oral Premalignant Lesions. 
Clinical Cancer Research, 2007. 13(12): p. 3753-3758. 
199. Cheng, L., et al., Expression of nucleotide excision repair genes and the risk for squamous cell 
carcinoma of the head and neck. Cancer, 2002. 94(2): p. 393-397. 
200. Yu, H., et al., Association between Single Nucleotide Polymorphisms in ERCC4 and Risk of 
Squamous Cell Carcinoma of the Head and Neck. PLoS ONE, 2012. 7(7): p. e41853. 
201. Zeller, C., et al., SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is 
downregulated in breast cancer. Oncogene, 2003. 22(19): p. 2972-83. 
202. Rimkus, C., et al., Prognostic significance of downregulated expression of the candidate 
tumour suppressor gene SASH1 in colon cancer. British Journal Of Cancer, 2006. 95(10): p. 
1419-1423. 
203. Martini, M., et al., The candidate tumor suppressor SASH1 interacts with the actin 
cytoskeleton and stimulates cell–matrix adhesion. The International Journal of Biochemistry 
& Cell Biology, 2011. 43(11): p. 1630-1640. 
204. Meng, Q., et al., SASH1 regulates proliferation, apoptosis, and invasion of osteosarcoma cell. 
Molecular and Cellular Biochemistry, 2013. 373(1-2): p. 201-10. 
205. Puente, X.S., et al., Exome sequencing and functional analysis identifies BANF1 mutation as 
the cause of a hereditary progeroid syndrome. Am J Hum Genet, 2011. 88(5): p. 650-6. 
206. Mansharamani, M. and K.L. Wilson, Direct binding of nuclear membrane protein MAN1 to 
emerin in vitro and two modes of binding to barrier-to-autointegration factor. Journal of 
Biological Chemistry, 2005. 280(14): p. 13863-13870. 
207. Skoko, D., et al., Barrier-to-autointegration factor (BAF) condenses DNA by looping. 
Proceedings of the National Academy of Sciences, 2009. 106(39): p. 16610-16615. 
208. Margalit, A., et al., Barrier-to-autointegration factor is required to segregate and enclose 
chromosomes within the nuclear envelope and assemble the nuclear lamina. Proceedings of 
the National Academy of Sciences of the United States of America, 2005. 102(9): p. 3290-
3295. 
 
 
117 
 
209. Zhuang, X., et al., Dephosphorylation of Barrier-to-autointegration Factor by Protein 
Phosphatase 4 and Its Role in Cell Mitosis. Journal of Biological Chemistry, 2014. 289(2): p. 
1119-1127. 
210. Dykhuizen, E.C., et al., BAF complexes facilitate decatenation of DNA by topoisomerase IIα. 
Nature, 2013. 497(7451): p. 624-627. 
211. Bar, D.Z., et al., BAF-1 mobility is regulated by environmental stresses. Molecular biology of 
the cell, 2014. 25(7): p. 1127-1136. 
212. Takama, H., et al., Possible roles of barrier-to-autointegration factor 1 in regulation of 
keratinocyte differentiation and proliferation. Journal of dermatological science, 2013. 71(2): 
p. 100-106. 
213. Montes de Oca, R., et al., Barrier-to-Autointegration Factor Proteome Reveals Chromatin-
Regulatory Partners. PLoS ONE, 2009. 4(9): p. e7050. 
214. Segura-Totten, M., et al., Barrier-to-autointegration factor: major roles in chromatin 
decondensation and nuclear assembly. The Journal of Cell Biology, 2002. 158(3): p. 475-485. 
215. Sutton, D.N., et al., The prognostic implications of the surgical margin in oral squamous cell 
carcinoma. International Journal of Oral and Maxillofacial Surgery, 2003. 32(1): p. 30-34. 
216. Binahmed, A., R.W. Nason, and A.A. Abdoh, The clinical significance of the positive surgical 
margin in oral cancer. Oral oncology, 2007. 43(8): p. 780-784. 
217. Chandu, A., G. Adams, and A. Smith, Factors affecting survival in patients with oral cancer: 
an Australian perspective. International journal of oral and maxillofacial surgery, 2005. 34(5): 
p. 514-520. 
218. Nason, R.W., et al., What is the adequate margin of surgical resection in oral cancer? Oral 
Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 2009. 107(5): p. 
625-629. 
219. Kademani, D., et al., Prognostic factors in intraoral squamous cell carcinoma: the influence of 
histologic grade. Journal of oral and maxillofacial surgery: official journal of the American 
Association of Oral and Maxillofacial Surgeons, 2005. 63(11): p. 1599. 
220. Kulasingam, V. and E.P. Diamandis, Strategies for discovering novel cancer biomarkers 
through utilization of emerging technologies. Nature clinical practice Oncology, 2008. 5(10): 
p. 588-599. 
221. Viale, G., et al., Which patients benefit most from adjuvant aromatase inhibitors? Results 
using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Annals of 
Oncology, 2011. 22(10): p. 2201-2207. 
222. Khleif, S.N., J.H. Doroshow, and W.N. Hait, AACR-FDA-NCI Cancer Biomarkers Collaborative 
Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development. Clinical 
Cancer Research, 2010. 16(13): p. 3299-3318. 
223. Mallette, F.A., et al., RNF8- and RNF168-dependent degradation of KDM4A/JMJD2A triggers 
53BP1 recruitment to DNA damage sites. EMBO J, 2012. 31(8): p. 1865-1878. 
224. Lewis, J.S., et al., Extracapsular extension is a poor predictor of disease recurrence in 
surgically treated oropharyngeal squamous cell carcinoma. Modern Pathology, 2011. 24(11): 
p. 1413-1420. 
225. Hooten, N.N., et al., Poly (ADP-ribose) polymerase 1 (PARP-1) binds to 8-oxoguanine-DNA 
glycosylase (OGG1). Journal of Biological Chemistry, 2011. 286(52): p. 44679-44690. 
226. Le Page, F., et al., Poly(ADP-ribose) Polymerase-1 (PARP-1) Is Required in Murine Cell Lines 
for Base Excision Repair of Oxidative DNA Damage in the Absence of DNA Polymerase β. 
Journal of Biological Chemistry, 2003. 278(20): p. 18471-18477. 
227. Radhakrishnan, R., et al., Tissue microarray–a high‐throughput molecular analysis in head 
and neck cancer. Journal of oral pathology & medicine, 2007. 37(3): p. 166-176. 
228. Cattoretti, G., et al., Antigen unmasking on formalin-fixed, paraffin-embedded tissue 
sections. The Journal of Pathology, 1993. 171(2): p. 83-98. 
 
 
118 
 
229. Shi, S.R., M.E. Key, and K.L. Kalra, Antigen retrieval in formalin-fixed, paraffin-embedded 
tissues: an enhancement method for immunohistochemical staining based on microwave 
oven heating of tissue sections. Journal of Histochemistry & Cytochemistry, 1991. 39(6): p. 
741-8. 
230. Chow, K.-h., R.E. Factor, and K.S. Ullman, The nuclear envelope environment and its cancer 
connections. Nature Reviews. Cancer, 2012. 12(3): p. 196-209. 
231. Chan, H.L., et al., Biomarkers for breast cancer. 2011, Google Patents. 
232. Ren, W., et al., Structural Basis of SOSS1 Complex Assembly and Recognition of ssDNA. Cell 
Reports, 2014. 6(6): p. 982-991. 
233. Gu, P., et al., Single strand DNA binding proteins 1 and 2 protect newly replicated telomeres. 
Cell Research, 2013. 23(5): p. 705-19. 
234. Choi, E.K., et al., Heterogeneous expression of Ku70 in human tissues is associated with 
morphological and functional alterations of the nucleus. The Journal of Pathology, 2002. 
198(1): p. 121-130. 
235. Shintani, S., et al., Up-regulation of DNA-dependent protein kinase correlates with radiation 
resistance in oral squamous cell carcinoma. Cancer Science, 2003. 94(10): p. 894-900. 
236. Mazzarelli, P., et al., DNA end binding activity and Ku70/80 heterodimer expression in human 
colorectal tumor. World Journal of Gastroenterology, 2005. 11(42): p. 6694. 
237. Someya, M., et al., Immunohistochemical analysis of Ku70/86 expression of breast cancer 
tissues. Oncology reports, 2007. 18(6): p. 1483-1487. 
238. Mascolo, M., et al., Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) 
polymerase 1 and nestin predicts metastasizing behaviour of oral cancer. Histopathology, 
2012. 61(6): p. 1089-1105. 
239. Domagala, P., et al., PARP-1 expression in breast cancer including BRCA1-associated, triple 
negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast 
Cancer Research and Treatment, 2011. 127(3): p. 861-9. 
240. Rojo, F., et al., Nuclear PARP-1 protein overexpression is associated with poor overall survival 
in early breast cancer. Annals of Oncology, 2012. 23(5): p. 1156-1164. 
241. von Minckwitz, G., et al., Cytoplasmic Poly(Adenosine Diphosphate–Ribose) Polymerase 
Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With 
Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 2011. 29(16): p. 2150-2157. 
242. Datema, F.R., et al., Novel head and neck cancer survival analysis approach: Random survival 
forests versus cox proportional hazards regression. Head & neck, 2012. 34(1): p. 50-58. 
243. Liao, C.-T., et al., Identification of a High-Risk Group Among Patients With Oral Cavity 
Squamous Cell Carcinoma and pT1–2N0 Disease. International Journal of Radiation 
Oncology*Biology*Physics, 2012. 82(1): p. 284-290. 
244. Michikawa, C., et al., Clinical significance of lymphatic and blood vessel invasion in oral 
tongue squamous cell carcinomas. Oral oncology, 2011. 48: p. 320-324. 
245. Ebrahimi, A., et al., Nodal yield and survival in oral squamous cancer. Cancer, 2011. 117(13): 
p. 2917-2925. 
246. Camisasca, D.R., et al., Oral squamous cell carcinoma: clinicopathological features in patients 
with and without recurrence. ORL J Otorhinolaryngol Relat Spec, 2011. 73(3): p. 170-6. 
 
 
 
